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ABSTRACT
Biological systems are incredibly difficult to untangle. On a molecular level,
biological systems need to be analyzed by embracing high-dimensional genetic complexity
in experimental design. One approach to understanding a biological system like a human
organ (e.g., the normal brain) or disease state (e.g., brain tumor) is to identify conditionspecific factors – biomarkers – that discriminate between biological states. A biomarker
system is a group of biomarkers that are collectively associated with a phenotype. With
exponentially growing amounts of high-throughput RNA-seq data available for both
normal and different types of disease conditions, RNA-based biomarker systems, which
underlie complex traits, can be identified. By using a combination of several computational
biology approaches, including condition-specific gene co-expression networks (csGCNs)
analysis, systems genetics integration of tissue-specific gene regulatory networks
(tsGRNs), machine learning validation of biomarker systems, and dimensionality reduction
techniques, robust RNA-based biomarker systems can be identified for both normal and
disease states. In this Dissertation, I apply these methods to discover candidate biomarker
systems involved in human normal brain region-specific states and normal lung versus lung
tumor states. Chapter 1 provides overview of the field. Chapter 2 describes the
identification of potential biomarker systems for normal human brain sub-regions by GCN
network analysis. Chapter 3 shows the integration of csGCNs with lung-specific GRN to
identify control-target biomarker systems for normal and cancerous lung tissue. Chapter 4
describes all other tissue-specific csGCNs constructed by KINC.
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CHAPTER ONE
LITERATURE REVIEW OF BIOMARKER SYSTEM IDENTIFICATION IN HUMAN
BRAIN AND LUNG
Introduction
Systems genetics approaches are employed in order to thoroughly understand the
relationships between genotypes and phenotypes in complex traits and diseases[1]. Data
can be combined from different molecular levels, including genome, transcriptome,
proteome, metabolome, and epigenome[2]. The publically available datasets for studying
diseases include genomic, transcriptomic, or proteomic datasets measured with increasing
number of disease samples as well as the corresponding normal samples. These datasets
can give us the opportunity to discover gene-disease associations[3]. With the availability
of public high-throughput sequencing datasets, computational-based data analysis has
become an inexpensive way to find potential candidate genes that are associated with a
particular trait or disease type prior to any wet lab validation[4].

What is a biomarker?
A biomarker is a measurable element that can distinguish samples in different
conditions, often discriminating between wild-type and disease states[5]. A biomarker
system is a group of biomarkers that can discriminate between biological conditions. Many
molecular processes and complex traits are related to gene expression and regulation[6].
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Thus, it is crucial to identify gene sets that discriminate and possibly control complex
biological systems. Molecular biomarkers can be found in several different forms,
including DNA polymorphisms, condition-specific differentially expressed gene products
(RNA and protein), correlated gene output (gene co-expression) or interacting gene
products (protein-protein interaction), differential epigenetic marks, and varied metabolite
concentrations[7].
Biomarkers in cancer helps cancer detection, and can affect the cancer response to
treatment[8]. Cancer biomarkers can be divided into three categories: predictive,
prognostic, and diagnostic. Predictive cancer biomarkers are used to estimate the risk of
developing a cancer. Prognostic cancer biomarkers predict disease recurrence and disease
progression. Diagnostic cancer biomarkers can distinguish between different sub-cancer
types[9]. Due to the polygenic aspect of cancer, systems-level approaches such as
identifying multi-gene correlations, can be used to discover novel biomarker genes and
regulatory mechanisms[10]. Because there is tumor heterogeneity within and between
individual tumors, all biomarkers may not play role in tumorigenesis in all individuals[11].
Instead, different biomarker combinations may lead to a histologically similar but
molecularly distinct complex disease state[12]. Thus, systems-level methods should be
used to identify biomarker systems in specific cancer subtypes and in specific patients
when possible. For this Dissertation, I integrated gene co-expression network with gene
regulatory network systems to study how those biomarkers co-expressed and co-regulated
discriminate specific cancer types.
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Recently, with the high-throughput datasets for both normal and disease samples
available, biomarker identification can be performed using approaches like data reduction,
classification and visualization[13]. Data reduction refers to breaking down the whole
complex system into small pieces and studying the isolated molecules and their structure
in order to better understand the whole system[14]. Clustering, which groups data together
based on the relationship among elements in the data, is one data reduction method for
discovering biomarkers[15]. Classification is also a popular method that can predict
unknown samples based on previous training samples[16]. Classification tools include
using regression[17], support vector machine (SVM)[18], random forest[19], and artificial
neural networks[20]. A classification method I applied in this Dissertation is Gene Oracle,
which uses a deep learning neural network to test gene sets for classification potential[21].
Another method, multidimensional data visualization, transforms complex gene expression
matrices into visual constructs to better understand and interpreted complex relationships
between samples. For example, t-distributed Stochastic Neighbor Embedding (t-SNE),
which reduces the dimensionality of complex datasets, is one of the visualization methods
I used in this study[22]. t-SNE is less biased and knowledge independent for clustering and
is based only upon the gene expression pattern. Another technique for analyzing highthroughput datasets is network analysis. Similarity scores for each gene pair, like Spearman
correlation, Pearson correlation[23], and mutual information[24], reveal the relationship or
the patterns between gene expression profiles. I used these techniques to identify
biomarkers and biomarker systems in different human organs and conditions.
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Normal and abnormal complex traits are associated with different biomarker systems
Studying the gene expression patterns on normal and abnormal samples helps us to
better understand the specificity of each condition. For example, the human brain is a
complex system that consists of many sub-regions, which can control different canonical
functions, such as thoughts, memory, and movement[25]. Each brain function is controlled
by the regulation of gene expression in different sub-regions[26]. It is crucial to understand
gene expression patterns revealing normal molecular structure and function in different
brain

sub-regions[27].

Fortunately,

“normal” brain transcriptome profiles
for thirteen different sub-regions of
normal brain are available from the
GTEx database[28].
Cancer is still the most common
disease worldwide[29]. It can start
almost anywhere in human body[30].
Cancer cells originate from normal
cells, but even within a single tumor,
Figure 1.1 t-SNE results for normal samples and
tumor samples. (A) Normal samples containing 53
tissue types from GTEx (v6p). (B) Tumor samples
containing 33 tumor types from TCGA. Each color
represents samples from one tissue type, and each
number represents the cluster identified by sample
enrichment for t-SNE results. Samples from same
tissue can form multiple clusters.
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different

cells

become

cancerous

independently. This process is known
as

intra-tumor

heterogeneity[31].

Cancers can be separated into several
different subtypes based on histology

and molecular profiles[32]. Figure 1.1 shows how global gene RNA expression patterns
sort normal samples from Genotype-Tissue Expression (GTEx) databases and tumor
samples from The Cancer Genome Atlas (TCGA). Each normal tissue or tumor subtype
has its unique gene expression pattern. Different groups of cancer driver genes and
pathways are involved in different cancer subtypes[33]. With the development of next
generation sequencing (NGS) techniques, the datasets for gene expression patterns of both
normal and disease samples across several human tissues make this data mining analysis
possible.
Biomarker identification is very useful in the cancer biology field[34]. By early
detection and precision cancer medicine, cancer patients can survive longer today[35]. The
screening for cancer biomarkers can detect cancer at an early stage and thus can improve
survival rate significantly[36]. For example, Arya et al. detected new and more specific
lung cancer biomarkers for early-stage screening of lung cancer by using biomarker-based
biosensors[37]. Furthermore, biomarkers can be used to develop precise targeted
therapies[38]. Ben-Hamo et al. identified pathway-level biomarkers across multiple tumor
types that are sensitive to different compounds by integrating pathway knowledge with
large-scale drug sensitivity, RNAi, and CRISPR-CAS9 screening data from cancer cell
lines to optimize patient-specific therapeutic strategies[39]. With more targetable
biomarkers being identified, precision cancer medicines have been designed for the
treatment of solid tumors[40]. For example, pertuzumab and trastuzumab are two drugs
which are designed for breast cancer patients with human epidermal growth factor receptor
2 (HER2) gene amplification[41].
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Brain cancers are one of the most common and diverse cancers. They can be
classified with more than 100 brain cancer entities[42]. Due to the complexity of the brain,
it is hard to identify the exact location of tumorigenesis[43]. By targeting region-specific
biomarker genes and comparing expression patterns of those genes in normal brain with
brain cancers, priority regions and region-specific candidate gene sets for tumor formation
can be predicted. By constructing brain region-specific gene co-expression networks, one
can determine how well those brain region samples can be discriminated from each other.
Furthermore, through comparison of gene expression patterns of disease samples with
normal samples from the same tissue type, biomarker systems for a specific tumor can be
identified to better understand tumorigenesis. In this Dissertation, I describe the
construction of normal brain gene relationship networks and biomarker systems.
Another organ I examined for this Dissertation is the human lung. Lung cancer is
the leading cause of cancer death among both men and women[44]. The most common
types of lung cancer are adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC);
each contributes to approximately 40% and 25-30% of all lung cancer cases, with poor
response to chemotherapy and a low survival rate[45]. Gene expression patterns for the
two types of lung cancer are different. Distinct gene sets can be distinguished from LUAD
to LUSC. To improve the clinical therapy for different types of lung cancer, gene
expression-based classification and GRN-bound biomarker systems are needed. By
comparing condition-specific gene co-expression patterns on either normal or different
lung cancer samples with gene regulatory information, condition-specific biomarker gene
sets can be identified.
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A number of molecular biomarker genes have already been identified in lung
cancer[46]. For example, the most known ones in non-small cell lung carcinoma (NSCLC)
cases include the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase
(ALK), kirsten rat sarcoma viral oncogene homolog (KRAS), ROS proto-oncogene 1,
receptor tyrosine kinase (ROS1), HER2, RET proto-oncogene, MET proto-oncogene, BRAF

proto-oncogene,

serine/threonine

kinase

(BRAF),

phosphatidylinositol-4,5-

bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), neurotrophic receptor tyrosine
kinase 1(NTRK1), fibroblast growth factor receptor (FGFR)[46]. Some of those markers
can distinguish between LUAD and LUSC cancers and are used as diagnostic clinical
markers. These markers include desmoglein 3 (DSG3), NK2 homeobox 1 (NKX2-1) and
high–molecular weight keratins (KRTs), such as KRT7, KRT17, KRT5, and KRT6 (keratin
6A, keratin 6B, keratin 6C)[47]. The identification of biomarkers in specific lung cancer
types may help develop targeted therapies to treat lung cancer. However, previous studies
only focused on differentially expressed genes in different lung cancers. Gene interaction
and regulation relationships involved in different lung cancers have not been studied yet.

Public dataset resources
The databases used in this Dissertation are from TCGA for tumor samples and the
GTEx project for normal samples (Figure 1.1). TCGA is a database, which identifies DNA
changes in 33 types of cancer from 11,328 patients, including both tumor samples and a
few solid tissue normal samples (https://portal.gdc.cancer.gov)[48]. Not all 33 tissue type
samples contain solid tissue normal data. The GTEx database (v7 version) contains 11,688
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samples surveying 53 tissues from 714 donors (https://www.gtexportal.org)[28]. A gene
expression matrix was constructed from 1671 brain samples from 13 specific brain tissues.
For comparing normal and corresponding tumor type datasets directly, Wang et al.
developed a pipeline to unify RNA-seq data from GTEx and TCGA[49]. Raw sequencing
reads were obtained from GTEx and TCGA first, GTEx normal data were realigned with
solid tissue normal sample data in TCGA, and gene expression was re-normalized and
batch effect biased removed for both datasets by running ComBat in the R package
SVAseq[50] for each study. Only cancer types in TCGA solid tissue normal samples were
unified with GTEx normal samples. Thus, this unified data contains samples from 13
tissues. This pipeline allows us to compare data from different conditions and find any
potential causal genes for disease.
Other public databases available for computational analysis include the database of
Genotypes and Phenotypes (dbGaP)[51], the UK Biobank[52], PsychENCODE[53],
human brain single cell RNA-seq analysis[54]. dbGaP is a database that aims to identify
the relationships between genotype and phenotype using methods including genome-wide
association analysis, medical sequencing, molecular diagnostic assays, association
between genotype and traits[51]. The UK Biobank is also a biomedical database collecting
genotype data with their clinical phenotypes to improve public health. The database
contains axiom genotype array, including whole genome genotyping, to capture rare and
coding variation and markers relevant to specific phenotypes[52]. The PsyENCODE
project aims to discover non-coding regulatory elements according to genetic variants for
both healthy and disease-affected human brain samples[53]. Another database that can also
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be used for normal brain is called single cell RNA-seq analysis from NCBI database. These
data sets contain gene information from all of the major neuronal, glial, and vascular cell
types in human cerebral cortex[54].

Biomarker discovery at the edge
In order to better understand the mechanisms for tumor pathogenesis, different
systems approaches can be used for studying different levels of gene expression and
function[55]. Levels include individual gene (node), pairwise (edge), and multiple edges
(networks decomposed into modules). The mechanisms of differential gene expression at
these three levels are due to genetic and epigenetic variation that may lead to a specific
phenotype. The variation may be present in coding and non-coding sequences in the
genome. For exploring important genes in specific conditions, many analyses, such as
DNA sequence alterations, copy number alterations, gene expression pattern differences,
and post-transcriptional modifications, can be studied[56].
For mRNA gene expression, differential expression (DE) analysis between control
and treated samples is a useful approach to detect potential candidate genes for specific
traits. DE analyses compare data from different conditions and find any potential causal
genes for disease. DESeq2 is a quantitative analysis of comparative RNA-seq data to
identify differentially expressed genes across samples[57]. For example, Zhang et al.
identified 1,230 differentially expressed genes between liver cancer samples and normal
samples, including 632 significantly down-regulated genes and 598 significantly upregulated genes[58]. This method is useful in identifying differentially expressed genes in
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different conditions, yet there are often thousands of genes that can be differentially
expressed between different conditions. These massive biomarker systems often confound
biological interpretation.
Besides how individual genes are differentially expressed under different
conditions, one also wants to know the relationships of those important genes; how do
genes relate with each other according to gene expression profiles for samples in a specific
condition or a phenotype. A gene co-expression network (GCN) is a common gene
relationship data structure which can identify relationships between genes by performing
correlation analysis based on the gene expression profiles[23] (Figure 1.2 A-C). In a GCN,
each node represents a gene or gene product. A pair of nodes is connected by an undirected
edge if they have significant co-expression relationship. A group of highly connected genes
form GCN subnetwork “modules” that could be controlled by the same gene regulatory
networks and possibly be involved in same or similar biological pathways.
B
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B

B
A

A
A

A

B

F
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D
C
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Figure 1.2 Biological networks representing different information levels. (A) A dot

represents gene (node) itself. (B) An edge represents two genes that are correlated in their
expression levels. (C) A module represents a group of genes that correlated together. (D) A
module that represents regulatory relationships of a group of genes. Node represents gene or
gene product, and edge represents the regulatory relationships among them.
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With the development of transcriptomics and next generation sequencing (NGS),
co-expression networks can be constructed using RNA sequencing data for either normal
samples and disease samples to identify the disease associated biomarker gene sets[59].
GCN analysis can be performed on hundreds of samples to identify gene correlation
patterns. Thus, this method can be used for the publicly available datasets for normal
samples and disease samples to identify biomarker systems in specific disease type.
There are several ways to construct a GCN. I used the approach called KnowledgeIndependent Network Construction (KINC) (https://github.com/SystemsGenetics/KINC),
which employs gaussian mixture models (GMMs) to cluster samples before pairwise
correlation[60]. As the utilization of GCNs increases, a framework is needed to compare
findings across GCNs. The downloaded RNA sequencing data are gene expression
matrices (GEMs), where rows represent genes, columns represent samples from different
tissue types or experimental conditions, and numbers in each cell are the expression level
of the particular gene in the particular sample[61]. GEMs were first processed and
normalized with KINC software before performing pairwise gene correlation tests, thus
reducing outliers to give cleaner input datasets. In this way, the KINC computational
workflow is unique because it de-convolutes mixed‐condition (e.g., mixed tumor samples)
expression patterns across GCNs. Thus, without providing KINC with a known knowledge,
gene expression relationships, including nodes, edges, and modules in different conditions
can be identified for both tumor samples and normal human brain samples.
In addition to GCN, another network analysis approach is to construct gene
regulatory network (GRN). A GRN is a directed network of genes, regulatory elements,
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and regulators that describes the mechanisms of spatial and temporal gene expression in an
organism[62]. Nodes in a GRN directed network can be protein transcription factors (TFs)
as well as non-coding RNAs (e.g., miRNA, lncRNA) and metabolites. TFs regulate gene
expression by binding to the regulatory elements of target genes[63]. The GRN is important
for understanding a development process because it can reveal genes that control the
activation of others in an ordered fashion[64]. Construction of tissue-specific GRNs help
uncover regulatory mechanisms underlying the relationship between target and regulator
genes in complex human disease[65].
One way to construct a GRN is to use Bayesian approaches using gene expression
profiles in the form of a directed acyclic graph (DAG)[66]. It constructs the qualitative
properties of gene regulatory networks by using a combination of two mathematical areas:
probability and graph theory that combine the data with prior knowledge. The input gene
expression profile data should be locally learned and select the most suitable GRN structure
by using search and score method, then combine the previously known knowledge to
estimate each gene’s probability values and establish the dependent causality for nodes[67].
However, this method is computationally intensive, which requires longer running times
especially for data with a high dimensionality[68].
Another method for constructing GRNs is based on the gene co-expression
networks[69]. Tissue-specific GRNs for 38 human tissue data from GTEx v6[70] was
constructed by Sonawane et al. by combining gene co-expression data with protein-protein
interaction (PPI) information and the DNA motif information. Each tissue network was
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then used to identify tissue-specific regulatory edges and nodes. They concluded that
highly correlated genes are more likely to be regulated by same transcription factor[71].
Nodes in a GCN and GRN represent genes and can be integrated as a combined
network. Two nodes in a condition-specific undirected GCN edge suggested the two genes
could be co-regulated leading to a shared molecular function. Thus, directed GRN edges
leading to these nodes suggests that the mechanism by which the GCN edge might be
regulated is causal[72]. By comparing condition-specific GCNs for one tissue type (normal
and disease type samples) with normal tissue-specific GRNs, one can not only expand
biomarker systems but also provide evidence for regulatory mechanisms underlying the
normal or diseased condition. In this Dissertation, I integrate lung and lung tumor GRNs
and GCNs.

Dissertation outline & broader impacts
In addition to describing biomarker system discovery workflows, this Dissertation
provides potential biomarker systems of relevance to the human brain and lung. During my
studies, I constructed GCN for GTEx normal brain, identified sub-region-specific nodes
and edges, and further identified several candidate biomarkers for different brain regions.
Condition-specific GCNs were constructed from normal and cancer lung (LUAD and
LUSC) datasets, and those condition-specific GCNs were mapped with normal lung
specific GRN to detect co-regulated gene sets in specific tumor type. These biomarker
systems can be further examined to understand how they regulated in normal and aberrant
states.
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The major contribution of this study is to extract biomarker systems in regionspecific normal brain, as well as normal lung and lung tumor conditions, integrating gene
regulation mechanisms with biomarker genes, and providing new insights about
mechanisms in forming different brain regions and lung tumors. By adding gene regulatory
information to the existing GCNs, this study discovers novel biomarkers and provides
candidate regulatory mechanisms. This study is transformative because it studies human
normal brain and lung cancer at a polygenic level instead of individual genes, which should
be more informative. Our biomarker identification methodology can be applied to other
human diseases or specific traits that will help us better understand human disease in a
whole genome level and can discover more different disease-specific gene pair biomarkers.
By utilizing several computational biomarker discovery methods, including
machine learning classification, visualization, and GRN-GCN integration, I discovered
specific sets of potential candidate biomarker systems involved in human normal brain subregion development and lung cancer. Chapter 2 describes the identification of potential
biomarker systems for specific brain sub-regions by constructing condition-specific GCNs.
Chapter 3 applies a similar approach and compare GCN with GRN to identify biomarkers
for specific lung tumor. Chapters 4 constructs tissue-specific csGCNs for other tissue type
tumors by using KINC v1.0 workflow and also constructs a deeper normal brain regionspecific GCN by using a newer version of KINC V3.4. This Dissertation utilizes similar
workflows to discover potential biomarker gene pairs in both normal condition and
different types of tumors.
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CHAPTER TWO
EXPLORATION INTO BIOMARKER POTENTIAL OF REGION-SPECIFIC BRAIN
GENE CO-EXPRESSION NETWORKS
This Chapter is from an open-source work published under the Creative Commons
Attribution 4.0 International License:
Hang Y, Aburidi M, Husain B, Hickman AR, Poehlman WL, Feltus FA. Exploration into
biomarker potential of region-specific brain gene co-expression networks. Sci Rep. 2020
Oct 13;10(1):17089. doi: 10.1038/s41598-020-73611-1. PMID: 33051491; PMCID:
PMC7553962.

Abstract
The human brain is a complex organ that consists of several regions each with a
unique gene expression pattern. Our intent in this study was to construct a gene coexpression network (GCN) for the normal brain using RNA expression profiles from the
Genotype-Tissue Expression (GTEx) project. The brain GCN contains gene correlation
relationships that are broadly present in the brain or specific to thirteen brain regions, which
I later combined into six overarching brain mini-GCNs based on the brain's structure. Using
the expression profiles of brain region-specific GCN edges, I determined how well the
brain region samples could be discriminated from each other, visually with t-SNE plots or
quantitatively with the Gene Oracle deep learning classifier. Next, I tested these gene sets
on their relevance to human tumors of brain and non-brain origin. Interestingly,I found that
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genes in the six brain mini-GCNs showed markedly higher mutation rates in tumors relative
to matched sets of random genes. Further, I found that cortex genes subdivided head and
neck squamous cell carcinoma (HNSC) tumors and pheochromocytoma and
paraganglioma (PCPG) tumors into distinct groups. The brain GCN and mini-GCNs are
useful resources for the classification of brain regions and identification of biomarker genes
for brain related phenotypes.

Introduction
The human brain is a complex system encompassing countless cells that coalesce
into hundreds of different regions and patterns of functional connectivity[25]. The
coherence between brain regions results in canonical functions like vision, language, and
memory[73]. The complexity of the brain is mainly due to the spatial and temporal
alteration of large amounts of gene expression during developmental specification and
maturation[73]. However, the region-specific description and control of gene expression
patterns across the human brain has yet to be fully revealed.
Fortunately, recent high-resolution genome wide transcriptome profiling studies
provide deeper insight into brain gene expression, especially in the context of diseaseassociated expression shifts in different brain regions. For example, Twine et al[74] studied
transcriptome profiles from both healthy brains and brains from patients with Alzheimer’s
disease (AD). They found significant differences in gene expression levels, splicing
isoforms, and alternative transcription start sites between healthy and AD brains. Another
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group created a gene expression model based on transcriptome datasets of the healthy
human brain from the Allen Brain Atlas[75]. This model can be used to identify potentially
new candidate genes implicated in neurological diseases using machine learning[27]. Other
studies include identifying gene expression patterns related to developmental origin of
brain regions, brain functions, and brain-specific diseases like autism[76]–[78]. A brain
transcriptome resource I leveraged in this study is from the Genotype-Tissue Expression
(GTEx) project[78] that characterized 54 tissues from 948 human donors. Thirteen of those
tissues were from specific regions of the human brain.
With the increasing number and diversity of high-resolution human brain gene
expression datasets, it is becoming easier to detect polygenic biomarker systems relevant
to a specific medical condition or brain region. For example, using pairwise gene
expression correlation tests across genes in a gene expression matrix (GEM), a gene coexpression network (GCN) can be constructed and utilized to detect co-functional gene
sets[60], [79]–[81]. In a GCN, each node represents a gene or gene product, and two nodes
are connected by an edge if they have a significant co-expression relationship. A group of
highly-connected genes in a GCN have a higher likelihood of being functionally related
relative to a group of poorly connected genes. I construct GCNs using software called
Knowledge-Independent Network Construction (KINC), which employs gaussian mixture
models (GMMs) to cluster samples before a pairwise correlation calculation[79]. KINC
deconvolutes mixed-condition pairwise expression profiles into condition-specific edges
that can be merged into a condition-specific GCN.
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Condition-specific GCNs encompass candidate biomarker systems relevant to that
condition. The effectiveness of the biomarkers to discriminate conditions can be formally
tested using machine learning and other classification techniques. For example, Gene
Oracle is a software package that implements a deep learning model to classify biological
samples using gene expression features as input[21]. In the Gene Oracle algorithm,
expression profiles of candidate gene sets are tested for significant non-random
classification potential of sample types (i.e. classification labels). The gene sets are then
decomposed into the most discriminatory candidate biomarker gene sets. In this approach,
the relevance of a biomarker system is formally quantified and refined to the core
biomarker features.
In this study, our goal was to identify condition-specific GCNs for normal human
brain regions. Towards this goal, I constructed a brain GCN using a GEM derived from 13
brain RNA-seq datasets obtained from the GTEx project[28]. I deconvoluted the brain
edges into brain region mini-GCNs and characterized highly interconnected genes. I then
used Gene Oracle to classify the input brain samples with these mini-GCNs to test their
biomarker potential on normal brain regions. Finally, I tested if the brain region-specific
genes tumor expression profiles were able to discriminate the brain from non-brain human
tumors.

Materials and Methods
Input data and gene expression matrix (GEM) preparation
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All available gene-level TPM (transcripts per million) files for 13 normal brain
region samples were downloaded from the Genotype-Tissue Expression (GTEx) project
version 7[28]. 1671 samples were downloaded–each containing measurements of 56,202
genes—and merged into a GEM. The matrix underwent preprocessing steps, including log
base 2 transformation, quality control, and quantile normalization, using the
preprocessCore R library. The Kolmogorov–Smirnov test (KS Dval> 0.15) was performed
to test for outlier samples. No samples qualified as an outlier, so I continued with a quantile
normalization of the matrix to reduce any technical noise. All FPKM (fragments per
kilobase of gene per million read pairs) files for GBM, LGG, HNSC, and PCPG patients
were downloaded from TCGA using the GDC Data Transfer Tool[82]. 1431 samples with
60,483 genes were aggregated into a GEM. The GEM underwent the same preprocessing
steps as the GTEx GEM.
Gene co-expression network construction
KINC (https://github.com/SystemsGenetics/KINC) was used to identify gene
correlation relationships within the normalized GTEx brain GEM. The algorithm calculates
correlation for each gene pair after clustering samples using GMMs. Only clusters with
equal to or more than 30 samples underwent Spearman correlation. I submitted 50,000
KINC similarity jobs on the Open Science Grid[83] by using the OSG-KINC similarity
workflow[84]. The workflow was accomplished using the Pegasus Workflow
manager[85]. Normalized TPM expression values less than 0 were ignored. KINC
similarity output was transferred to Clemson University’s Palmetto Cluster via Globus.
The KINC significance threshold of 0.8961 was found by using a random matrix
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thresholding (RMT) algorithm within the KINC thresholding script. The GTEx brain GCN
was then constructed by extracting all edges with correlations> 0.8961 using the KINC
extract script. 183 linked community modules (LCMs) were identified by the linkcomm R
packages with a minimum cluster size of 3 edges[86]. The full GCN is shown in
Supplemental Table A-1.
Edge and module sample enrichment analysis
All identified modules and edges in the GTEx brain GCN were tested for sample
label

enrichment

using

the

KINC.R

package

(https://github.com/SystemsGenetics/KINC.R). A Fisher’s exact test with a Hochberg pvalue correction was used as the default arguments to the analyzeNetCat function. The
sample label enrichment lists for modules as well as edges are shown in Supplemental
Table A-2 and A-3. In the sample label enrichment for modules, I considered to use the pvalue threshold of 1E−3 for significantly enriched modules. The edges with p-value less
than 1E−10 were considered as significantly enriched edges because this p-value is close
to maximizing the number of edges and nodes. The number of enriched edges for each
specific region with the adjusted p-value less than 1E−3, 1E−5, 1E−15, and 1E−20 were
also collected separately and the t-SNE visualization was run for each of those gene sets
(Supplemental Table A-4 and Supplemental Figure B-1). Furthermore, I calculated the
number of regions that each edge, module, and eQTL belonged to. eQTL datasets for 13
brain regions samples were also downloaded from the GTEx project V7[28]. regionspecific edges and modules were selected to construct GTEx sub-brain GCNs. LCM
modules were also tested for functional term enrichment using the FUNC-E package
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(https://github.com/SystemsGenetics/FUNC-E), which uses a Fisher’s exact test similar to
the David28 method of functional enrichment. For cross-module comparisons, enriched
terms were considered significant if the Bonferroni-corrected p-value was less than 0.001.
Functional annotations performed include Gene Ontology[87], Reactome[88], Pfam[89],
Interpro[90], and Mendelian Inheritance in Man (MIM)[91]. The full module functional
enrichment list is shown in Supplemental Table A-5. region-specific edges for each region
also underwent functional term enrichment analysis, which is shown in Supplemental
Table A-6. Moreover, gene type for all currently identified genes was downloaded from
Ensembl Biomart (https://useast.ensembl.org/info/data/biomart/). All genes from GTEx
dataset, genes from brain GCN as well as each region-specific gene were counted for
calculating the protein-coding and non-coding gene percentages. This result is shown in
Supplemental Table A-7 and Supplemental Table A-8.
t-SNE analysis
A dimensionality reduction and visualization pipeline were performed using either
a full or partial GTEx brain GEM as the input. This allowed us to compare how varying
subsets of genes were able to separate the selected brain regions. It was performed using
the principal component analysis (PCA) and t-distributed stochastic neighbor embedding
(t-SNE) Python sklearn packages[22]. Each t-SNE run created a two-dimensional
randomly initialized embedding, in which samples were clustered into different subgroups. The perplexity used for each run was 30. This pipeline was performed on the GTEx
brain GCN GEM containing 1691 genes for 1671 samples, as well as the six GTEx subbrain GCN GEMs containing region-specific genes for 1671 samples. I also performed
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PCA and t-SNE on the TCGA cancer GEM, which contained region-specific genes for
1431 tumor samples, in order to segregate the four TCGA tumor types. TCGA datasets
were downloaded from TCGA data portal[92].
Brian region classification
I used a two phase, bottom-up classification approach of a feedforward neural
network, known as Gene Oracle[21] (https://github.com/SystemsGenetics/gene-oracle), to
classify brain regions, and thus, identify the region-specific gene biomarkers. Gene Oracle
uses a multilayer perceptron (MLP) feedforward neural network[93] to identify biomarker
gene sets with a significant classification accuracy when comparing to sets with equal
number of random genes. Gene Oracle can also sort genes within a gene set according to
their classification rates. This is done by breaking the gene set down into its most
discriminatory features, followed by iteratively appending genes to explore new
combinations. The architecture of the network consists of a total of five layers: an input
layer with a size equivalent to the size of the gene set, three hidden layers (512, 256, and
128 units, respectively), and a final layer for classification. The three hidden layers utilize
rectified linear unit (ReLU) activation function[94]. In Gene Oracle phase I, six merged
brain region gene sets were screened for a significant classification potential that would
allow for classification of the samples into 13 brain regions. For each brain gene set, 50
random size-controlled gene sets were selected from all genes in the input GTEx GEM and
evaluated using the same classifier. Size-control means that each corresponding gene in the
random list was within 10% of the size of the original gene from the region-specific list.
The mean classification accuracy was calculated for the 50 random gene sets and compared
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with the corresponding brain gene set accuracy. For example, the cortex set that contained
40 genes was compared to 50 different sets of 40 random size-controlled genes for
classification accuracy. A 10-fold cross validation procedure was applied to train and test
the model. A gene set was chosen to undergo further analysis if the classification accuracy
was higher than that of the average of the corresponding random sets with a statistical
significance of p < 0.001 (using Student’s t test). In Gene Oracle phase II, the gene set that
exhibited a significant classification potential underwent a combinatorial decomposition in
order to discover the most discriminatory genes in the set. Three brain gene sets with a
smallest number of genes, including the cortex gene set, the spinal cord gene set, and the
substantia nigra gene set, underwent Gene Oracle phase II to detect candidate genes for
better classification.
To compare the results of Gene Oracle phase II, I utilized Random Forest[95] to
run the classification for the five brain sets that were significant in Phase I of Gene Oracle.
Random Forest was also used to highlight the important features (i.e. genes) using its built
in functions of scikit-learn library in Python. Once Random Forest identified the important
features, they were compared to the ones identified by Gene Oracle. The Random Forest
model consisted of 100 trees, where the value of the threshold for early stopping in tree
growth is 1E−7. The built-in scikit-learn function “RandomForestClassifier” was used to
construct the Random Forest model in Python.
Tumor gene mutation rates
Somatic mutations for GBM, LGG, HNSC, PCPG, and KIRC tumor subtypes were
downloaded from TCGA[92]. TCGA reported mutations from four different
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polymorphism detection methods including Muse[96], Mutect[96], Sniper[96] and
Varscan[97]. I downloaded the Muse method dataset and counted the number of tumors
with at least one mutation, the number of genes mutated in a tumor, and the number of total
mutations present in a tumor. I summed these values for candidate gene sets and the sizecontrolled random gene sets of equal number. The randomized control genes were counted
a hundred times and then an empirical p-value (p < 0.01) was determined for each
candidate gene set. The absence or presence of an IDH mutation (IDH1/IDH2/IDH3) in
LGG and GBM samples was also collected and used for t-SNE visualization.

Results
Brain region-specific gene co-expression network (GCN) construction
I wanted to identify region-specific gene co-expression patterns in the brain using
KINC[60]. To do this, I analyzed 1671 GTEx gene expression profiles from 56,202 genes
across 13 different brain regions. Prior to GCN construction, the GTEx GEM was
preprocessed by log2 transformation of the expression values, applying the Kolmogorov–
Smirnov test to remove outlier distributions, and performing quantile normalization on the
GEM. The full brain GCN contains 1691 nodes and 7812 edges (Supplemental Table A-1;
Fig. 2.1 A—right panel). The GCN was further dissected into 183 linked community
modules (LCMs)[86].
I then performed sample label enrichment for all modules and edges in the brain
GCN (Supplemental Tables A-2 and A-3). In the sample label enrichment for modules,
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Figure 2.1 Normal brain gene co-expression network. (A) The right panel
represents the whole gene co-expression network (GCN) constructed from 1671
GTEx brain RNA-seq samples from 13 different brain regions. The left panel is the
corresponding t-SNE visualization for the 1691 brain GCN genes where RNA
expression profiles sorted regions into multiple clusters. Each color represents a
different region shown in the legend. (B) Six brain region mini-GCNs are shown on
the right side of each panel. Corresponding t-SNE visualization pictures for those
region-specific genes are shown on the left side of each panel. Non-black dots in each
t-SNE plot represent the corresponding region-specific samples and black dots
represent samples from all other regions. For all basal ganglia specific gene sets, red,
orange and yellow dots represent caudate basal ganglia, nucleus accumben basal
ganglia, and putamen basal ganglia samples respectively. The red and orange dots
from cerebellum and cerebellar hemisphere specific gene sets represent cerebellum
and cerebellar hemisphere samples respectively. All red dots from other regionspecific gene sets represent the particular region-specific samples.
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I considered to use the p-value threshold of 1E−3 for significantly enriched modules.
Because modules contain different numbers of genes, there are very few modules that are
enriched significantly in only one brain region. Thus, I calculated the sample label
enrichment for each edge. The edges with a p-value less than 1E−10 were considered to be
significantly enriched because this p-value is close to maximizing the number of edges and
nodes. The number of enriched edges for each specific region with the adjusted p-value
less than 1E−3, 1E−5, 1E−15, and 1E−20 were also collected separately and the t-SNE
visualization was ran for each of those gene sets (Supplemental Table A-4 and
Supplemental Figure B-1). One can see from the results that even though the threshold pvalue of 1E−15 had more edges and nodes in total, most regions had a decrease in the
number of specific edges. For example, the number of edges and nodes in the basal ganglia,
cerebellum, and spinal cord regions was lower when the threshold was 1E−15 compared
to a p-value threshold of 1E−10. Exceptions to this included the cortex specific edges,
which increased slightly in number, and the hypothalamus where the number of specific
edges increased strikingly. Furthermore, the t-SNE plots showed that the region-specific
genes cannot separate samples very well for p-value thresholds of 1E−3 and 1E−5, while
they can for thresholds of 1E−10, 1E−15, and 1E−20. Thus, I used a p-value of 1E−10 as
the threshold of significance for the sample label enrichment for edges.
The identified region-specific sub-GCNs with adjusted p-value less than 1E−10 are
shown in Fig. 2.1 B—right panel for each region. Global attributes for both full brain GCN
and region sub-GCNs are shown in Table 2.1. For example, the 160 brain caudate (basal
ganglia) samples significantly contributed to 2076 edges (p < 1E−10) that contained 690
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nodes and connected 131 modules. These brain caudate (basal ganglia) nodes had high
connectivity (k = 6.02), and among the 690 nodes, 33,554 eQTLs were found in the GTEx
database. The average gene expression values for enriched nodes (μ=3.89, σ=2.49) was
higher than all GTEx gene expression values (μ=0.57, σ=3.34).

Figure 2.2 Brain region-specific GCN attributes. (A) Number of link community modules
unique to 0–13 brain regions. (B) Number of edges unique in 0–13 brain regions. (C) Number
of region-specific edge associated GTEx eQTLs unique in 1–13 brain regions.

I counted the number of modules, edges, and eQTLs that were enriched for each
brain region (Fig. 2.2). Most modules were enriched in multiple brain regions. However,
there were three modules enriched in only one specific brain region, and one more module
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enriched in two brain regions. Similar to the modules, the majority of the edges were not
enriched in one single region, with the exception of 434 that were present in only one brain
region. Most eQTLs were found in only one brain region, and the number of eQTLs
decreased when there were more shared regions, except for the number of eQTLs shared
by all 13 brain regions. For each region’s enriched edges, I also counted how many of them
were associated with other regions (Supplemental Figure B-2). Most edges were enriched
in more than one brain region.

For the 434 region-specific edges, I identified edges that were unique for one region
as shown in Table 2.2. For example, 139 nodes and 200 edges were found that are only
enriched in brain caudate (basal ganglia) samples. Only 22 genes out of the 139 unique
caudate genes contained eQTLs and 917 eQTLs were found in total. On average, each
unique node had 41.68 eQTLs. Of the 13 brain regions, ten contained region-specific edges.
According to the anatomy of the brain, I combined some of the region-specific edges
together to form six region-specific edge lists. For example, the basal ganglia consists of
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the caudate, the nucleus accumbens, and the putamen. Therefore, I combined those regionspecific edges together. The cerebellar and cerebellar hemisphere samples were taken from
the same site in the brain, so I combined those two lists together. The hippocampus only
contained two region-specific edges, therefore it was not large enough to construct its own
sub-GCN. In total, six overarching region-specific edge lists were generated from the brain
GCN. I used these new sets to construct sub-GCNs and visualize their gene expression
patterns.
To see how region-specific gene subsets separate the brain regions, I performed tSNE. t-SNE is a dimensionality reduction algorithm for visualization of high dimensional
data into two or three dimensions17. Using all the genes from the full brain GCN as input
to t-SNE, the regions separated at different degrees (Fig. 2.1 A—left panel). The main
observation was the separation of the cerebellum and cerebellar hemisphere samples from
other region samples. The expression pattern for other brain regions mixed together and
could not be distinguished.
Using different sets of region-specific sub-GCN genes as input to t-SNE, the region
distribution varied (Fig. 2.1 B—left panel). For example, the basal ganglia region,
consisting of caudate basal ganglia, nucleus accumbens basal ganglia, and putamen basal
ganglia samples, did not separate basal ganglia samples from other region samples based
on the expression patterns of the 145 unique basal ganglia genes. This pattern was also
observed in the cortex samples when using the 40 unique cortex genes as input. However,
the expression pattern for 28 spinal cord unique nodes separated the spinal cord samples
from any other brain region samples. Also, cerebellum specific genes were able to separate
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cerebellum and cerebellar hemisphere samples from all other samples. The t-SNE
visualization for each region based on its enriched nodes is shown in Supplemental
Figure B-3.
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I performed functional enrichment analysis on full brain GCN modules
(Supplemental Table A-13) as well as brain region-specific nodes (Supplemental Table A6). Table 2.3 lists the region-specific module information, and Table 2.4 lists their
corresponding functional enrichment results.
To determine if the region-specific edges were coding or non-coding genes, I
counted the gene classes for all GTEx input genes, brain GCN genes, as well as each
region’s specific gene list (Supplemental Table A-7). About one third of the GTEx input
genes are protein-coding genes, but of those from the brain GCN and the region-specific
gene lists, almost all the genes are protein-coding. Interestingly, among the 1,671 genes
from brain GCN, there are 39 genes that are lncRNA (Supplemental Table A-8). This could
be our future topic of study.
Brain region biomarker validation
The six brain region-specific gene sets identified by GCN analysis were evaluated
using Gene Oracle software which determines classification accuracy of a set of target
genes relative to an identical number of random genes. I ran Gene Oracle phase I over 1671
samples from 13 different brain regions. Genes of each region’s specific set were used as
features to classify samples into 13 brain regions. The output accuracy of each region’s
specific set is shown in Fig. 2.3 A. The following five sets showed significant classification
potential: substantia nigra, spinal cord, hypothalamus, cortex, and cerebellum.
Surprisingly, the sixth set (basal ganglia) was not significant as random genes provided a
similar accuracy. To show the precise classification and the contribution of a regionspecific gene set to each class, I generated a confusion matrix for each set (Fig. 2.3 B).
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Darker green correlates to a higher classification accuracy. I observed that in most cases
the region-specific gene sets classified their respective regions more accurately than other
sets.

Figure 2.3 Gene Oracle classification of brain regions with brain regionspecific edges. (A) Classification accuracy (X-axis) of region-specific gene sets
(Y-axis; green bars) versus matched number of random genes (red bars) over 1671
GTEx brain samples from 13 different brain regions. (B) Confusion plot showing
precise classifications (diagonal boxes) and misclassified samples for each
region-specific gene sets. The upper number in the diagonal boxes indicates the
number of samples that are correctly classified, and the lower number indicates
it’s percent for each class. Other boxes show a number of misclassified samples.
The three smallest significant sets of these five sets were selected for full
combinatorial analysis with phase II of Gene Oracle. These included the spinal cord,
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cortex, and substantia nigra gene sets. Gene Oracle identified the genes which contributed
the most to overall classification accuracy (candidate genes) for each of these regionspecific sets. Figure 2.4 contains heatmaps which show the normalized frequency of a gene
in a subset at a given iteration of the combinatorial analysis for the spinal cord, cortex and
substantia nigra sets. The first three rows of the heatmaps had constant frequency values
because all possible combinations of genes were evaluated, hence all genes appeared
equivalently in the first three iterations. For the rest of the iterations, the distribution of the
frequencies became varied and the most frequent genes appeared. Using the heatmaps, I
determined the candidate genes of the three sets to be those with an aggregate frequency
of at least one-half the standard deviation above the mean. The rest of the genes were
considered “non-candidate” genes. Table 2.5 shows the candidate genes identified by Gene
Oracle for each of these three regions.

Figure 2.4 Combinatorial analysis of spinal cord, cortex and substantia nigra gene sets.
Heatmaps depicting the frequency of genes present in the classification subsets that were
generated at each Gene Oracle Phase 2 iteration. Each row is an iteration and each column is a
gene from the cortex/spinal/substantia nigra sets. Darker colors correspond to higher
frequencies.
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Due to computational constraints imposed by the large number of genes, I used a
Random Forest approach in lieu of Gene Oracle phase 2 for the hypothalamus and
cerebellum sets. I used feature_importances_() built in function to output the most
important features (i.e. genes), which were then considered candidates for these two
regions. To compare to Gene Oracle, I also ran Random Forest to identify the candidate
genes for spinal cord, cortex and substantia nigra. Candidate genes identified by Random
Forest are shown in Table 2.6. The genes denoted in bold are common between the two
methods.
To verify the classification potential for the candidate genes, I ran the Random
Forest again for each candidate set shown in Tables 2.5 and 2.6. Figure 2.5 shows, for each
region-specific set, the classification accuracy of (1) the original region-specific set, (2) the
candidate set identified using Gene Oracle, (3) the non-candidate set identified using Gene
Oracle, and to compare to Random Forest, (4) the candidate set identified using Random
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Forest, (5) the non-candidate set identified using Random Forest. Additionally, the
accuracy of each category was compared with the averaged accuracy of 50 random sets of
equal size of genes of each set. In all cases, the difference in accuracy from random is
highest in the candidate set and the lowest in the non-candidate sets. Furthermore, the
candidate set identified by Gene Oracle exhibits a higher difference than those identified
by Random Forest as shown in Fig. 2.5 A.

Figure 2.5 Classification potential for decomposed gene sets. (A) Classification
accuracies for the full region-specific gene sets (green) were compared to accuracies
of the candidate genes identified by Gene Oracle (blue), non-candidate genes
identified by Gene Oracle (gray), candidate genes identified by Random Forest
(orange), and non-candidate genes identified by Random forest (purple). (B) Same
as (A) but only for decomposed genes identified by Random Forest.
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Brain region biomarker potential for human brain tumors
I was interested to see how the brain region-specific genes could separate abnormal
brain samples. For each region-specific gene set, i ran t-SNE on 1,431 tumor samples with
four tumor types from The Cancer Genome Atlas (TCGA) as seen in Fig. 2.6. The tumor
types were glioblastoma multiforme (GBM), lower grade glioma (LGG), head and neck
squamous cell carcinoma (HNSC), and pheochromocytoma and paraganglioma (PCPG).
Most of the region-specific genes could separate HNSC and PCPG tumors apart, while
LGG and GBM samples could not be separated. The t-SNE visualization based on 40
cortex specific genes separated HNSC samples and PCPG samples into different subgroups. For each region-specific t-SNE plot, the brain tumors (both LGG and GBM) were
separated into 2–3 sub-groups. The t-SNE visualizations of four TCGA subtypes based on
enriched nodes for all 13 regions are shown in Supplemental Figure B-4. I also ran t-SNE
of the 40 cortex specific genes on TCGA tumor data for gender, race and stage. None of
these factors could separate tumor clusters (Supplemental Figure B-5). t-SNE visualization
on only brain tumors with IDH mutation annotation is shown in Supplemental Figure B-6.
For whole brain GCN genes, LGG and GBM were separated apart, but some LGG samples
were more similar to GBM samples. The IDH mutant samples were more clearly separated
from non-IDH mutant samples. LGG and GBM samples could not be separated using
region-specific genes, while IDH mutated samples could be separated with non-IDH
mutated samples. IDH mutated samples were also divided into several subgroups using
each region’s specific gene list. For example, for t-SNE based on substantia nigra specific
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genes, almost all of the upper samples contain an IDH mutation, while almost all of the
bottom samples did not contain an IDH mutation.

Figure 2.6 t-SNE visualization of region-specific genes on TCGA tumor data. t-SNE
was performed using TCGA RNAseq data from brain region sub-GCN genes. 1431 tumor
samples from four tumor subtypes are shown. Tumor RNA expression profiles sorted
regions into multiple clusters. Each color represents different regions. Red represents
GBM; green represents HNSC; blue represents LGG; yellow represents PCPG.

In order to see if the brain region-specific genes were important in different tumor
types, I aggregated the mutation rates of five TCGA tumor types [GBM, LGG, HNSC,
PCPG, and kidney renal clear cell carcinoma (KIRC)] for the six region-specific gene sets
and one kidney gene set which contains the 20 most mutated genes in KIRC and their
corresponding randomized control genes. As shown in Table 2.7, the number of mutated
genes for all seven gene sets in GBM, LGG and HNSC was significantly higher than that
for their corresponding random sets (p-value < 0.01). However, the number of mutated
sub-brain specific genes was not significantly higher than the random sets in PCPG tumor.
In KIRC tumors, only cerebellum specific gene set were significantly higher in mutated
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genes than randomly mutated genes. None of the other five region-specific gene sets had
significantly numbers of higher mutated genes relative to a similar number of random
genes.

Discussion
In this study, I constructed a normal brain GCN and identified edges that were
specific to 13 brain regions. After merging edges from similar regions, six brain regionspecific GCNs were identified. Functional enrichment for both region-specific modules
and the six sub-GCNs provided evidence that these genes encode brain functions. For
example, as shown in tissue-specific genes functional enrichment analysis in Supplemental
Table A-6, several edges specific for the substantia nigra were associated with the
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production of dopamine and other neurotransmitters, as well as their response to
amphetamine and nicotine. In addition, both the hypothalamus and basal ganglia specific
gene sets are enriched for cilium related functions, such as cilium, cilium movement, motile
cilium, and cilium assembly. Cilia play an important role in modulating neurogenesis, cell
polarity, axonal guidance and possibly adult neuronal function, which is related to brain
development[98]. As expected, the brain GCN encodes brain function.
A prime motivation of our study was to test our approach to identify brain
biomarker systems that can distinguish brain regions based upon region-specific coexpression relationships. The idea was that co-expressed genes unique to a brain region
would be better biomarkers for sorting samples into normal and aberrant states that involve
that region of the brain. Using t-SNE, I visualized the brain region clustering potential of
these gene sets. Some gene sets separated regions well (e.g. spinal cord genes, substantia
nigra genes, and cerebellum and cerebellar hemisphere genes), while others could not
separate samples from each brain region. These visual results suggested that the biomarker
sets have varied discriminatory potential.
The six brain region-specific gene sets were also evaluated for quantitative
classification potential using a deep learning approach implemented in Gene Oracle to both
classify samples from 13 brain regions and identify core candidate gene subsets which play
the most important role in brain region classification. Using phase I of Gene Oracle, I
examined the classification potential of six gene sets. All sets, except the basal ganglia set,
showed significant mean classification accuracy relative to the mean accuracy of the same
size of random gene sets (Fig. 2.3 A). The confusion matrix of the basal ganglia gene set,
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which showed the precise classification and the contribution of each set to each region
classification in Fig. 2.3 B, possibly explains why the basal ganglia specific gene set had
low classification accuracy. Because the caudate, nucleus accumbens and putamen all
belong to the basal ganglia, they are physically located very close to each other. The
combined basal ganglia gene set consisted of genes that were only enriched for one of these
three regions. However, when I ran Gene Oracle classification, I did not combine the above
three regions together. Thus, for example, it is possible that the basal ganglia specific gene
sets misclassified caudate into nucleus acumens or putamen. The same explanation can be
applied to the case that most of the sets show a high percentage of misclassification
between cerebellar hemisphere and cerebellum. From the confusion plots, I can tell that
similar brain regions had the trend to be misclassified with each other, which decreased the
classification accuracy. Interestingly, some region-specific gene sets showed the ability to
more accurately classify their regions. For example, when the genes of the spinal cord set
were used as features, the model was able to classify the spinal cord samples with a 99%
accuracy, which is higher when compared to other regions. These results reflect the fact
that the region-specific genes can hold a higher predictive power for that region.
I used condition-specific GCN analysis via KINC to identify biomarker candidates.
I was able to go one step further using Gene Oracle phase II and Random Forest feature
extraction algorithms to identify genes which contributed the most to the overall
classification accuracy (candidate genes) for each of the smallest three region-specific sets
(substantia nigra, cortex and spinal cord sets). Once compared to the important genes
identified by Random Forest, Gene Oracle showed a higher accuracy and a larger increase
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in accuracy when these genes were used as features (Fig. 2.5 A). For example, the blue box
represents the accuracy increase once candidate genes of substantia nigra, cortex, and
spinal cord candidate gene sets were used as feature inputs to Gene Oracle. This represents
a much higher accuracy compared to the random set (red) and the set identified through the
use of Random Forest as a classifier model (orange). More interestingly, Gene Oracle
provided deeper resolution than t-SNE. The left panels of Fig. 2.1 B illustrate the large
overlap between brain regions whereas Gene Oracle was able to easily discriminate the
regions with high accuracy compared to random gene sets. The confusion matrices support
this point as well, see Fig. 2.3 B. These results demonstrate the power in utilizing deep
learning technology for biomarker gene discovery.
After characterization of the biomarker potential of the brain genes on normal
GTEx brain regions, I wanted to test the biomarker systems for classification potential of
aberrant brain tissue. For this test, I chose LGG and GBM brain tumors as well as tumors
that originated from other organs. t-SNE visualization was performed using TCGA tumor
RNA-seq expression profiles for the brain genes on samples from four different tumor
types. Most of the region-specific genes could separate HNSC and PCPG tumors while
LGG and GBM samples could not be separated. Interestingly, even though LGG and GBM
samples could not be separated apart, those tumor samples can still be separated into
several subgroups. This is partially due to the status of the IDH1/2 mutation which is very
common in LGG[99] (Supplemental Figure B-6). The IDH mutant gliomas can be further
divided into smaller sub-groups as well. Moreover, the t-SNE plots showed that the 40
cortex specific genes separated HNSC samples and PCPG samples into different sub-
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groups. As with the normal brain samples, there was mixed potential of the genes to sort
human tumors.
Interestingly, I found that many of the brain region-specific GCN edges were
mutated in tumors. As shown in Table 2.7, the number of mutated genes in all six brain
region-specific gene sets was significantly higher than the number of mutated genes in the
list of size-controlled random genes for GBM, LGG, and HNSC (p-value less than 0.01),
but not for PCPG and KIRC. GBM and LGG represent tumors that originate in the brain.
HNSC is not a brain cancer, but it originates in the squamous cells that line the moist,
mucosal surfaces inside the head and neck, such as mouth, nose, throat, larynx, sinuses, or
salivary glands[100]. PCPG originates mainly on the adrenal gland and only a few cases
of paraganglioma localize in the neck and head[101]. KIRC originates from the kidney.
The brain region-specific gene sets had a higher mutation rate in the brain tumors (LGG
and GBM) than other tumors when compared to random genes. Interestingly, all brain
region-specific gene sets had significantly higher mutation rate than random genes in
HNSC, which indicates that these six brain specific gene sets could be important in HNSC
tumor formation. Furthermore, cerebellum specific gene sets showed significantly higher
mutation rate for KIRC, which means these 78 cerebellum specific genes may also play an
important role in KIRC formation and development. The kidney specific gene set had
higher mutation rates in almost all five listed tumor types. This might be because I chose
the top 20 most mutated genes in KIRC as identified in the TCGA data portal. The 20
chosen genes are not necessarily specific to kidney tumors, and therefore could also be
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highly mutated in other tumors. Thus, these genes that are mutated in KIRC also have
significantly high mutation rates in HNSC, LGG and PCPG.
In conclusion, this study describes how condition-specific candidate biomarker
systems can be discovered using GCN analysis and I describe how machine learning
approaches can be used to measure the quality of the biomarker sets. Further, I believe that
the significant condition-specific relationships are worthy of deeper analysis into why they
are present in specific brain regions. In the future I intend to further investigate the
biological significance of these edges, including an examination of normal region eQTL
regulation of these gene datasets to find important transcription factors and binding sites
that may become altered during tumorigenesis.
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CHAPTER THREE
IDENTIFICATION OF CONDITION-SPECIFIC REGULATORY MECHANISMS IN
NORMAL AND CANCEROUS HUMAN LUNG TISSUE

Abstract
Lung cancer is the leading cause of cancer death in both men and women. The most
common lung cancer subtype is non-small cell lung carcinoma (NSCLC), comprising about
85% of all cases. NSCLC can be further divided into three subtypes: adenocarcinoma
(LUAD), squamous cell carcinoma (LUSC), and large cell lung carcinoma. Specific
genetic mutations and epigenetic aberrations play an important role in the developmental
transition to a specific tumor subtype. The elucidation of normal lung versus lung tumor
gene expression patterns and regulatory targets yields biomarker systems that discriminate
lung phenotypes (i.e., biomarkers) and provide a foundation for the discovery of normal
and aberrant gene regulatory mechanisms. I built deep condition-specific gene coexpression networks (csGCNs) for normal lung, LUAD, and LUSC conditions. Then, I
integrated normal lung tissue-specific gene regulatory networks (tsGRNs) to elucidate
control-target biomarker systems for normal and cancerous lung tissue. I characterized coexpressed gene edges, possibly under common regulatory control, for relevance in lung
cancer. Our approach demonstrates the ability to elucidate csGCN:tsGRN merged
biomarker systems based on gene expression correlation and regulation. The biomarker
systems I describe can be used to classify and further describe lung specimens. Our
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approach is generalizable and can be used to discover and interpret complex gene
expression patterns for any condition or species.

Introduction
Even though lung cancer incidence has shown a gradual decline in the past decade
in the United States, it remains the leading cause of cancer death in both men and women
with its mortality rate exceeding breast, prostate, colorectal, and brain cancers
combined[102]. Lung cancer comprises approximately a quarter of all cancer deaths and is
strongly associated with environmental risk factors including smoking, and exposure of
toxic chemicals that trigger some forms of interstitial lung disease[103]. In 2018, it is
estimated that about 2.1 million new people were diagnosed with lung cancer with 1.8
million deaths worldwide[104].
As evidenced by tumor heterogeneity, lung cancer can originate from different
tissue contexts, be classified into multiple subtypes, and be present with varied molecular
characteristics and biological phenotypes[105]. The most common subtype of lung cancer
is non-small cell lung carcinoma (NSCLC), comprising about 85% of all cases. NSCLC
can be further divided into major subtypes, including adenocarcinoma (LUAD), squamous
cell carcinoma (LUSC), and large cell lung carcinoma[106]. LUAD and LUSC can be
distinguished between each other by the complex expression patterns of multiple genes.
For example, Charkiewicz et al. identified 53 biomarker genes that can classify LUAD and
LUSC with 93% accuracy[47]. Further research by Valeria et al. identified 69 distinct
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tumor prognostic determinants that had significant impact on clinical factors for LUAD or
LUSC, which include key factors on tumor growth, cell cycle, and tumor progression
pathways. Those determinants were quite different in LUAD and LUSC, and some of them
had opposite impact on these two types of lung cancer[107].
Among candidate lung tumor genes, p63 is the best single marker to separate
LUAD from LUSC[108]. Genes related to LUAD are more related to tight junction and
cell adhesion molecules, while LUSC related signature genes are more correlated with cell
communication pathways[109]. A proper differentiation between lung cancer subtypes at
the molecular level is crucial especially for mapping appropriate treatment strategies[110].
For example, the overexpression of epidermal growth factor receptor (EGFR), which is
involved in about 60% of NSCLC tumors and present in about 20% of LUAD tumors,
currently has precision medicine implications in treating lung cancer[111]. Furthermore,
mutations in other genes, such as anaplastic lymphoma kinase (ALK), kirsten rat sarcoma
viral oncogene homolog (KRAS) and ROS proto-oncogene 1 receptor tyrosine kinase
(ROS1), can also be factored into targeted therapies[112].
Excellent genomics data repositories exist for discovery of complex gene
expression patterns between normal and diseased conditions including transcriptome and
DNA polymorphism profiles from The Cancer Genome Atlas (TCGA) and the GenotypeTissue Expression (GTEx) projects. TCGA is a cancer genomics database, which provides
a rich amount of high-throughput DNA sequencing and clinical data for different types of
cancer based on tissue of origin (portal.gdc.cancer.gov)[82]. TCGA contains both tumor
and non-tumor tissue samples excised near the tumor, which are annotated as “solid tissue
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normal”. The GTEx project is the public resource database that contains high-throughput
data from non-diseased individuals, which are collected from 54 non-diseased tissue types
for various molecular assays (www.gtexportal.org)[28].
In order to directly compare GTEx and TCGA RNA-seq datasets, Wang et al.
developed an RNAseq pipeline to process and unify RNA-seq data from GTEx and
TCGA[49]. First, raw sequencing reads were obtained from GTEx and TCGA, re-aligned
based on the solid tissue normal samples from TCGA, and re-quantified using RSEM[113].
Finally, batch effects were corrected by running ComBat in the R package SVAseq[50].
Because this pipeline required solid tissue normal to unify data from different sources, only
thirteen human tissues of origin were unified in total. Of high importance, the unified
normal and tumor Gene Expression Matrices (GEMs) built with this pipeline can be
processed in the same experiments to identify gene expression shifts between normal and
tumor states.
One method to detect condition-specific (i.e. disease) gene expression patterns is
gene co-expression network (GCN) analysis, an approach that constructs a gene
relationship network where co-expression of genes across multiple samples or specific
conditions implies biochemical co-functionality[114][59]. There are several tools to
construct GCNs including weighted correlation network analysis (WGCNA)[115],
Bayesian based network construction[116], multiscale embedded gene co-expression
network analysis[117], and Knowledge-Independent Network Construction (KINC)[118].
In our study, I utilized KINC v3.4 to construct condition-specific GCNs (csGCNs), which
employs gaussian mixture models (GMMs) for clustering for each gene pair to identify
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gene-gene co-expression clusters that can then be tested for association with experimental
conditions such as cancer subtype[119].
While GCNs describe correlated gene expression output, the underlying factors
regulating gene output are represented by gene regulatory networks (GRNs). A GRN
identifies relationships between regulators and their target genes in a tissue-specific
context[120]. In most cases, transcriptional regulation can be determined by the complex
interactions among cis and trans transcription factors (TFs) and their target genes[121].
There are many different approaches to construct GRNs, including several linear models,
such as Bayesian network (BN) models[122], dynamic Bayesian network (DBN)
models[122], Boolean network[123], and ordinary differential equation (ODE)
models[124]. For example, GRNVBEM is an algorithm utilizing Bayesian network[125];
SCODE[126] and GRISLI[127] are the algorithms using linear ODE-based methods.
Another method for constructing GRN is based on GCNs[69]. Of relevance to human
tumor studies, Sonawane et al. constructed tissue-specific GRNs for 38 human tissues from
GTEx in which they combined gene co-expression and protein-protein interaction (PPI)
information as well as the DNA motif information together to identify tissue-specific
network elements[70]. This study showed that correlated genes were more likely to share
a common transcriptional control mechanism[71]. Thus, linking co-expressed genes in
either normal condition or disease condition with normal tissue GRNs should be helpful to
identify mechanisms underlying diseases, including specific cancer subtypes.
The molecular mechanisms underlying complex traits including normal lung
development or lung tumor formation are discoverable using systems genetics approaches.
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In this report, I aimed to discover lung biomarker systems which I define as co-functional
gene sets that not only discriminate specific conditions or phenotypes (i.e., biomarkers) but
also integrates gene regulation information as a foundation for the discovery of genetic
control mechanisms between gene expression states. To achieve this goal, I first extracted
pairwise gene expression correlations with KINC v3.4 from the unified GTEx-TCGA
GEMs to construct normal lung and lung tumor csGCNs. The csGCNs were then combined
with a normal lung tissue-specific GRN (tsGRN). This integrated gene expression platform
enabled the elucidation of candidate control-target biomarker systems for normal and
cancerous lung tissue which I will discuss. As more condition-specific GEMs and GRNs
are reported, our approach will improve the resolution of complex biomarker systems for
lung cancer but can be applied more generally to any organ context.

Materials and Methods
Input Data and Gene Expression Matrix (GEM) Preparation
All available gene expression FPKM files for GTEx normal samples, TCGA solid
normal samples, TCGA tumor samples of each tissue type were downloaded from the data
records of Wang’s research [https://doi.org/10.6084/m9.figshare.5330593][49]. All files
were quantile normalized and corrected for batch effects. For each tissue type, I merged
those GTEx normal, TCGA solid normal and TCGA tumor files together into one GEM
using GEMprep [https://github.com/SystemsGenetics/GEMprep.git]. The conditionspecific sample annotation matrix was collected from the original GEMs of each condition.
The merged GEM then underwent the log2 transformation, quantile normalization, and
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Kolmogorov-Smirnov test (KS Dval>0.15) by using the normalization function in
GEMprep. No outlier sample was removed by the KS test analysis for each tissue. For
unified lung dataset, the total of 1,415 samples were downloaded, including 313 GTEx
normal lung samples, 110 TCGA normal samples, 489 TCGA LUAD tumor samples, and
503 TCGA LUSC tumor samples. Each file contains the measurements of 19,648 genes.
The density plot for unified lung GEM, which is the gene expression distribution of each
sample, is shown in Supplemental Figure B-7.
Gene Co-expression Network Construction
The

Knowledge

Independent

Network

Construction

(KINC)

software

(https://github.com/SystemsGenetics/KINC) was used to identify gene correlation
relationships from the gene expression data. KINC was performed on an NVIDIA DGX-2
workstation. KINC v3.4 was pulled in the Docker environment. The network construction
used gaussian mixture models (GMMs) to identify clusters before calculating correlation
for each cluster, for each gene pair. Only clusters with equal to or greater than 30 samples
underwent Spearman correlation and up to five clusters could be detected. The number of
identified clusters was between one and five. All log2 transformed and normalized FPKM
expression values less than 0 and more than 15 were ignored. I retained all gene pairs with
a Spearman correlation value greater than 0.5 or less than -0.5. Because I used a very low
minimum similarity score threshold, I found many potential edges. A Pearson’s power
analysis test for the GMM method was performed to filter the low powered clusters using
the pwr.r function in the pwr R package. Alpha setting limited the Type I error to the
significance of 0.001, and power setting allows 20% Type II error. The condition (GTEX,
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TCGA_NORMAL, LUAD, LUSC) specificity test was performed to generate conditionspecific subnetworks. Linear regression for quantitative conditions and two z-tests for
proportions of categorical data was performed. For linear regression test, both r-square
values and p-values were calculated to obtain condition-specific edges. R-square value
counts for the variation of the trend line, and significant p-value indicates how well the
samples in the cluster showed the correlation pattern. I set the r-square value to greater than
0.30 and p-value less than 0.001. After extraction of the condition-specific networks, two
cases of biased condition-specific edges were removed, including lack of differential
cluster expression (DCE) and unbalanced missing data, by using KINC.R package
(https://github.com/SystemsGenetics/KINC.R). The package used a Welch’s one-way
ANOVA test to identify DCE and a Student’s t-test to compare missing data. Edges without
significant p-values for both tests (a p-value more than 0.001 for Welch’s ANOVA test and
a p-value less than 0.1 for Student’s t-test) were removed. A series of summary plots were
generated to check condition-specific response in the network. The last filtering step was
to rank the network based on the correlation value (similarity score), the r-square value (for
quantitative conditions) and corresponding p-value also by using KINC.R package. Rank
was performed for our condition-specific networks, but no edges were removed. This
ranking method helped prioritize higher ranked edges. The final step was to visualize the
whole network using cystoscope as well as the KINC 3D network viewer[119]. The 3D
layout screenshot was shown in Supplemental Figure B-8. The full GCN is shown in
Supplemental Table A-9.
Network Integration and Analysis
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The

GTEx

GRNs

were

generated

by

Sonawane

et

al.

(https://sites.google.com/a/channing.harvard.edu/kimberlyglass/tools/gtex-networks)[70].
Some GRN edges were only found in lung tissue, while some other edges were enriched
in several tissue types but were still considered as tissue-specific edges. The full GRN
network is shown in Supplemental Table A-9. The lung condition-specific GCN
subnetworks were mapped to the GTEx normal lung GRN network. I selected the TFs that
can regulate at least one nodes of the edge as well as both nodes of the edge from each
condition-specific subnetwork. DEG analysis was performed between GTEx normal lung
GEM and LUAD as well as GTEx normal lung GEM and LUSC by using DESeq2_1.30.1
in R 4.0 (https://bioconductor.org/packages/release/bioc/html/DESeq2.html). The input
lung GEM was obtained from https://doi.org/10.6084/m9.figshare.5330539. For each
comparison, I determined the TF/TR ratio value, mean and standard deviation in each
sample condition and performed a Student’s t-test to determine if a given ratio was
significantly different from normal to cancer conditions (p < 0.001). All ratio comparisons
are shown in Supplemental Table A-11. I also determined which TFs and TRs were upregulated or down-regulated using DESeq2 results. Group classification was performed on
condition-specific gene sets using the deep learning software, Gene Oracle[21]
(https://github.com/SystemsGenetics/gene-oracle). The MLP model contained five layers:
an input layer with the size of gene set, three hidden layers of 512, 256 and 128 units using
rectified linear unit (ReLU) activation function[94], and a final later for classification.
Confusion matrices were generated using Gene Oracle. Functional enrichment analysis
was performed using all genes and TFs in LUAD and LUSC combined networks with
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Toppfun (https://toppgene.cchmc.org/). I focused on the pathway results. Genes shown in
the same pathway, as well as the target genes regulated by TFs in the same pathway, were
selected, aiming to find any candidate genes associated with specific lung cancers.

Results
Unified Normal and Tumor Sample Clustering with t-SNE
The first step to discover biomarker systems based on csGCNs and tsGRNs was to
obtain and explore normal and tumor RNA-seq transcriptome profiles. Unified GTEx and
TCGA RNA-seq GEM files were obtained from Wang et al.[49]. The profiles that belong
to the same tissue of origin were merged into tissue-specific unified GEMs. For example,
the GEM files containing GTEx normal lung samples, TCGA solid lung normal samples,
TCGA LUAD samples, and TCGA LUSC samples were merged into one lung-specific
unified GEM. Each unified GEM for thirteen tissues underwent further normalization as
described in the Methods section.
To further explore the clustering patterns for different tissues, I performed tdistributed stochastic neighbor embedding (t-SNE)[22] visualization (Figure 3.1). Some
tissue datasets did not form distinct clusters due to the small number of GTEx normal
samples or TCGA solid tissue normal samples. For example, the bladder dataset did not
show a definitive cluster pattern because there were too few samples for the GTEx normal
condition (n=11) and TCGA tumor-flanking “solid tissue” normal condition (n=19) to form
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Figure 3.1. t-SNE visualization of gene expression patterns for thirteen unified tissues and
tumor subtypes. Each tissue type contains GTEx normal, TCGA solid normal, and at least one
tumor subtype. Each color represents a different condition. Cancer samples are labeled as
orange, red and yellow; GTEx normal samples are labeled as green, light green and cyan;
TCGA solid tissue normal samples are labeled as blue. Samples are separated into multiple
clusters based on FPKM RNA-seq gene expression data. (A) t-SNE plots with tissue samples
that did not form a cluster. (B) t-SNE plots with TCGA solid tissue normal samples grouped
between GTEx normal samples and TCGA tumor samples. (C) t-SNE plots with TCGA solid
tissue normal samples grouped together with GTEx normal samples.
clusters. The same situation also occurred for the cervix dataset (Figure 3.1A). For those
tissue types that did form clusters, some tissue datasets cannot separate TCGA solid tissue
normal samples apart from either GTEx normal or TCGA tumor samples. For example, for
prostate, salivary, and stomach datasets, the TCGA solid tissue normal samples were
located between GTEx normal samples and TCGA tumor samples situation. It was difficult
to determine if the TCGA solid tissue normal samples in these organs were truly “normal”
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samples (Figure 3.1B). Of those tissues with more than one cancer type, the lung samples
represented the only tissue where normal samples, regardless of the source, grouped
together as a single cluster and each cancer subtype clustered separately (Figure 3.1C). I
chose the lung as a target organ to construct condition-specific lung GCNs using KINC
followed by integrating the GTEx normal lung GRN with the condition-specific GCN to
identify possible regulatory mechanisms in both normal lungs and lung tumors.
Lung Condition-Specific Gene Co-Expression Network (csGCN) Construction
For deeper analysis, I selected the unified and normalized lung GEM that contained
313 GTEx normal lung samples, 110 TCGA solid lung normal samples, 489
adenocarcinoma (LUAD) samples, and 503 squamous cell carcinoma (LUSC) samples to
construct a csGCN. The density plot for the normalized lung GEM is shown in
Supplemental Figure B-7. Using this lung GEM as input, a csGCN was constructed using
KINC version 3.4.2. First, KINC identified GMMs and retained any pairwise Spearman
correlation greater than |0.5| as a potential edge. KINC then ran a Pearson’s power analysis
to remove edges with insufficient power. Next, by providing to KINC the sample condition
information, it performed a linear regression test for each edge with each quantitative
condition (r-square > 0.3 and p-value < 0.001) or two z-score tests of proportions for
categorical conditions (p-value < 0.001). Edges with association to a condition were
labeled with that condition resulting in condition-specific subnetworks. The four
conditions for the unified lung GEM include GTEx normal, TCGA normal, LUAD, and
LUSC.
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There are instances where edge associations can be biased. For example, if
expression of one gene is highly variable between conditions it will bias the pairwise
comparison to look condition-specific even if the other gene is not variable between
conditions. Additionally, samples with missing expression in one gene must be removed
prior to correlation analysis. If missing values tend to occur in one condition in only one
gene, then sample removal will bias the comparison to appear condition-specific. To
address these issues, KINC next employed a Welch’s one-way ANOVA test (to check for
conditional variation in both genes) and a Student’s t-test (to check for equal patterns of
missingness) to remove biased edges. Finally, remaining edges were ranked by their
correlation value (similarity score), r-square (for quantitative conditions) and pvalues[119]. All identified edges that were enriched in at least one condition formed the
full lung csGCN.
The full lung csGCN contained 7,868 genes and 58,415 edges, and an average
clustering coefficient <C>= 0.281 (Supplemental Table A-9; Figure 3.2). The global
network attributes for both the full network and each condition-specific sub-network are
shown in Table 3.1. Connectivity, clustering coefficient, unique edge percentage, and
unique node percentage for each csGCN were calculated (Table 3.1). The clustering
coefficient is the measure of the overall tendency of nodes to form clusters or groups. For
the module-free scale-free network, <C> is usually very low[128]. The GTEx normal
csGCN contained the most nodes and edges, and the highest average clustering coefficient
(6,813 nodes, 53,233 edges, and <C>=0.291). The TCGA normal subnetwork was small
and contained had the lowest average clustering coefficient (36 nodes, 21 edges, and
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<C>=0). The TCGA normal subnetwork also had the least average connectivity (1.17),
least unique edge percentage (1.53%), and least unique node percentage (3.4%). The
LUAD specific subnetwork contained 530 nodes, 600 edges, and <C>=0.002. The LUSC
specific subnetwork contained 1,414 nodes, 1,694 edges and <C> of 0.062. A 3D network
visualization of lung GCN is shown in Supplemental Figure B-8 where one can observe
that the four csGCN subnetworks can be separated in four sub-clusters.

Figure 3.2. Unified lung condition-specific gene co-expression network (csGCN). The
full lung csGCN constructed from 1,415 lung RNA-seq samples from 4 different lung
conditions: GTEx normal lung, TCGA normal lung, TCGA LUAD tumor, and TCGA LUSC
tumors. The GCN is scale-free and contains 7,868 nodes and 58,415 edges.
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Condition-Specific Lung GCN and GRN Integration
The GTEx normal lung specific gene regulatory network (GRN) was downloaded
from Zenodo https://zenodo.org/record/838734[70]. The entire GTEx normal lung related
GRN is shown in Supplemental Table A-10. I then integrated the normal lung tsGRN with
our csGCNs. Edges in the normal lung GRN were selected where the TFs targeted at least
one node in LUAD and LUSC specific GCNs to obtain LUAD and LUSC GRN networks.
DEG analysis was then performed for each gene in the unified GEMs to identify
differentially expressed genes (DEGs) between GTEx normal lung and TCGA LUAD
conditions as well as GTEx normal lung and TCGA LUSC conditions. For both LUAD
and LUSC conditions, significant DEGs were determined for both a transcription factor
(TF) and its target gene (TR). TF or TR genes were considered as DEGs when their DEseq2
adjusted p-value was less than 0.001; gene expression directionality (e.g., up-/downregulation in tumor) was noted.
For each edge pair, the expression value of TF/TR ratio was calculated for samples
from GTEx normal, LUAD, and LUSC conditions. A Student’s t-test was performed
(p<0.001) to determine if the TF/TR ratio was significantly different between GTEx normal
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Figure 3.3. Summary of Regulatory Edges Between GTEx Normal Lung and 2 Types
of Lung Cancer. (A) Bar graphs calculating number of GRN edges between GTEx normal
lung tissue samples and LUAD (left panel) or LUSC (right panel) respectively for each
category. Blue bars represent the number of regulatory edges in total where TF regulated at
least one node in an edge from the LUAD/LUSC specific GCNs. Orange bars represent the
number of edges when both TF and TR were differentially expressed. Green bars represent
the number of edges when TF/TR ratio was significantly different between normal lung and
LUAD or LUSC. Red bars represent the number of significant edges when TF and TR were
both DEGs and TF/TR ratio is significantly different. For those significant edges, purple
bars represent TF was down-regulated in cancer while TR was up-regulated in cancer;
brown bars represent TF was up-regulated in cancer while TR was down-regulated in
cancer; pink bars represent both TF and TR were down-regulated; and bars represent both
TF and TR were up-regulated. (B) Heatmap distribution of regulatory edges comparing
between normal samples and two types of lung cancer with LUAD on the left and LUSC
on the right. For DEG lists, red means the gene was differentially expressed between normal
and cancer; grey means the gene was not a DEG. The up/down regulation, red means upregulation, blue means down regulation, and grey means not a DEG. For TF/TR ratio, red
means the ratio was significantly different between normal and cancer, and grey means the
ratio is not different.
lung and LUAD or LUSC conditions. The counts of each edge category and distribution
heatmap comparing regulatory edges from GTEx normal lung samples with different types
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of lung cancer samples are shown in Figure 3.3. The detailed DEG results and TF/TR ratio
comparison for condition-specific GRN edges are shown in Supplemental Table A-11. As
seen in Figure 3.3 and Table 3.2, there were 1,972 regulatory edges in total for nodes in
the LUAD specific csGCN. Among those edges, 1,497 edges contained both TF and TR
that were DEGs between GTEx normal lung and LUAD samples, 1,019 edges contained
TF/TR ratio that was significantly different between GTEx normal lung and LUAD
conditions, and 813 significant edges were DEGs and significantly different TF/TR ratios.
For the significant edges containing both situations, most (498) showed that the TFs were
down-regulated in LUAD versus normal while TRs were up-regulated, which means the
downregulation of the TFs could be related to the up-regulation of the corresponding target
genes that play roles in LUAD cancer development. The number of edges with significant
TF/TR ratios was similar for TF up/TR down, both TF down/TR down, and TF up/TR up
patterns (98, 128, and 89 respectively).
There were 4,037 regulatory edges in total with TFs targeting at least one node in
the LUSC csGCN. Among those edges, 2,229 were identified as significant edges as both
TFs and TRs were DEGs and the TF/TR ratio was significantly different between normal
to LUSC. The number of significant edges for all four conditions were similar (Figure 3.3A
and Table 3.2). The heatmap distribution was also performed for those edges. For the GRN
edges comparing GTEx normal and LUAD conditions, there were more down-regulated
TFs in LUAD than up-regulated TFs, but more up-regulated target genes. Thus, the TF
down/TR up pattern contains most significant edges. However, the up or down regulation
pattern was split in half for both TF and TR in GRN edges comparing GTEx normal and
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LUSC, so the significant edges showed similar number for each of the four conditions
(Figure 3.3B).

Figure 3.4. The merged triangle network of TFs from GRNs regulating both nodes in
csGCN subnetwork edges. (A) The merged network for GTEx normal lung subnetwork
mapped with GRN. (B) The merged network for TCGA LUAD subnetwork mapped with
GRN. (C) The merged network for TCGA LUSC subnetwork mapped with GRN. Pink round
nodes represent TFs, grey rectangular nodes represent genes that are both regulated by TFs
and exist in each csGCN subnetworks. A line with an arrow indicates a directed edge and the
line without arrow is the undirected edge. For lung cancer specific sub-networks, the name of
up-regulated DEGs are shown in red; the name of down-regulated DEGs are shown in blue;
non-DEGs were shown in black. GCN undirected edges are shown in grey. The directed edges
when TF/TR ratio was different from normal to cancer are shown in orange, while directed
edges when TF/TR ratio was not significantly different are shown as black.
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To identify gene pairs potentially controlled by common regulatory factors, I
selected csGCN edges where both nodes are the target of the same TF forming a triangle
network motif. The merged csGCN and GRN node and edge for LUAD and LUSC specific
networks are shown in Figure 3.4 and a Cytoscape file can be found in Supplemental Data.
Each TF that can regulate both nodes of a csGCN edge in lung tissue forms a triangle. Gene
names in red represented up-regulation in cancer, gene names in blue represented downregulation in cancer, and gene names in black represented non-DEG genes. For the edge
attribute, if the TF/TR ratio was significantly different between GTEx and lung cancer, the
directed edge color was orange. The detailed triangle edge information is shown in
Supplemental Table A-12.
Four triangles were found in LUAD, such that the TF targeting both nodes in a
LUAD specific GCN edge. For example, all three edges in triangle of ETV4 targeting both
ABCC5 and LIMS2 in the LUAD csGCN were DEGs. The up-regulation of ETV4 in
tumors is associated with down-regulation of both ABCC5 and LIMS2 in tumors. Further,
both the ETV4/ABCC5 ETV4/LIMS2 ratios were both significantly different between GTEx
normal condition and LUAD. In LUSC, 169 triangles were found that the TFs pointing to
both nodes in a LUSC specific csGCN edge were significant GRN edges.
Biomarker System Validation
In order to test the classification potential of our selected genes, a deep learning
algorithm called Gene Oracle performed sample classification according to input gene
expression patterns[21]. All nodes from the LUAD and LUSC merged triangle networks
were input into Gene Oracle as condition-specific gene sets to evaluate the cancer-type

63

classification accuracy of samples. The confusion matrix for each gene set analyzed is
shown in Figure 3.5 where the number of correctly classified samples are shown in the
diagonal boxes.
Most samples were classified correctly using the condition-specific gene
expression profile. Based on the gene expression of GTEx normal specific 1,459 genes, all
GTEx normal samples were correctly classified, while other groups had some misclassified samples. For both LUAD specific expression profile (13 genes) and LUSC
specific gene expression profile (150 genes), most samples were correctly classified. The
TCGA normal condition also had several mis-classified as GTEx normal which is
understandable given that they are both considered to be normal lung samples as further
evidenced by the t-SNE plot in Figure 3.1.

Figure 3.5. Gene Oracle classification confusion matrices from “triangle” csGCN nodes.
The number in the diagonal boxes indicates the number of samples that are correctly
classified, and other boxes show the number of misclassified samples. (A) The confusion
matrix for GTEx normal gene sets. (B) The confusion matrix for TCGA LUAD gene sets. (C)
The confusion matrix for TCGA LUSC gene sets.
Biomarker System Functional Enrichment Analysis
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By integrating the lung specific tsGRN network with csGCNs, I found specific
biomarker systems that might be involved in LUAD and LUSC tumor biology. Functional
enrichment

analysis

was

performed

on

these

gene

sets

with

ToppFun

(https://toppgene.cchmc.org/enrichment.jsp) using TFs and their target genes from each
triangle network as the input gene list. The annotation databases I tested included
REACTOME[88], KEGG[129], and Pathway Interaction Database (PID)[130]. The
ToppFun

enriched

pathways

can

be

found

in

Supplemental

Table

A-13.

In the LUAD csGCN, four TFs out of 180 were associated with the “transcriptional
mis-regulation in cancer” pathway (Bonferroni p=7.4E-3). These TFs were ETV1, ETV4,
ETV6 and ELK4. For selected TFs which targeted edges from TCGA_LUAD network, the
edge of ILVBL and LIMS2 was regulated by ETV1, ETV4 and ETV6 simultaneously. The
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edge of LIMS2 and ABCC5 was regulated by ETV4. LIMS2 had many edges in GTEx
normal csGCN, while both ILVBL and ABCC5 genes cannot be found in any nodes of the
GTEx normal csGCN. Both ILVBL and ABCC5 genes had higher percentage of somatic
mutations in LUSC relative to LUAD cases (Table 3.3).
For the LUSC csGCN, several genes were found related to DNA replication. The
pathway called “DNA replication” contained eleven out of 111 genes, including PSMA4,
PSMC5, E2F1, MCM5, GINS1, GINS2, CDC45, RFC4, RFC5, PRIM1, and PCNA. Several
edges can be found for those genes in the LUSC csGCN. For example, CDC45 forms an
edge with MAM5 and PCNA. Also, several of these eleven genes formed edges with the
same node. For example, SPC25 formed edges with RFC5 and PRIM1. The expression
pattern of these genes showed that most had differential expression between normal and
LUSC. Another pathway I identified was related to defective CSF2RA which causes
pulmonary surfactant metabolism dysfunction 5 (SMDP5). Four out of eight genes were
found, including SFTA3, SFTPA2, SFTPB, and SFTPD. It has been shown that a rare
missense mutation in SFTPA2 can cause idiopathic pulmonary fibrosis and lung
cancer[131]. These genes were all down-regulated in lung cancer and showed more downregulation in LUSC than LUAD samples. There were no shared GCN edges between these
four genes, but they do share the same TFs. Thus, the edges from LUSC specific GCN
containing these genes could be involved in this pathway and had function in forming
LUSC.
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I identified another four out of eight genes in the pathway called “defective
CSF2RA causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)” (Bonferroni
p=5.73E-3). Most selected genes from LUSC networks had higher mutation rates in LUSC
than LUAD. Among those genes, SFTPA2 had much higher mutation rate in LUSC than
LUAD. The expression pattern of the selected genes is shown in Table 3.4.

Discussion
Lung cancer is a highly complex disease. The subsets of lung tumors show diverse
patterns of gene expression. In this study, lung csGCNs were generated and were compared
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with normal lung specific tsGRNs. The number of edges and nodes enriched in TCGA
LUSC csGCN was approximately three times those in the TCGA LUAD csGCN, even
though the sample size was similar in the two conditions. Many unique edges were found
in LUAD and LUSC csGCNs, which indicated that the two lung cancer subtypes may have
distinct tumor gene expression profiles.
Many genes in the LUAD and LUSC csGCNs are known to be involved in cancer.
For instance, many prognostic gene determinants identified by Relli et al.[107], which
showed significantly different survival impacts on LUAD and LUSC patients, can be found
in the LUAD and LUSC csGCNs respectively. For example, many LUAD associated genes,
such as FOLR1, SFTA3, TMC5, and TMEM125, can be found in the LUAD csGCN
network. Furthermore, determinants showing negative prognostic impact on LUAD, but
positive impact on LUSC, such as DSG3, FOXE1, GRHL3, DLX5, and TMPRSS11D, can
be found in the LUSC csGCN. Yao et al. identified prognostic biomarkers in LUAD, which
contains twelve lnc-RNAs, nine mRNAs and one miRNA that were significantly (p<0.001)
associated with the overall survival with LUAD patients. Five out of nine mRNAs were
identified in the LUAD csGCN, including CCNE1, CCNB1, KIF23, CEP55, and
CHEK1[132]. Similarly, Dong et al. constructed lncRNA-miRNA-ceRNA network that
revealed pathological roles of the LUAD and LUSC. Only two of twenty mRNAs in LUAD
that were also identified by our LUAD specific GCN (UBE2C and CTHRC1), while nine
out of twenty mRNAs were identified in LUSC specific GCN, including SFTPA2, CLDN18,
SFTPB, SFTPD, NAPSA, CALML3, SPRR1B, KRT6B, and KRT5[133].
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Evidence shows that genes with high correlation and with similar functions are
more likely to be regulated by the same mechanism[71]. By performing functional
enrichment on genes and TFs in LUAD and LUSC csGCNs, I found several genes and TFs
participate in the same biological pathway. For the LUAD network, four TFs, ETV1, ETV4,
ETV6, and ELK4, were involved in the pathway called “transcriptional mis-regulation in
cancer”. All four TFs were normal lung and LUAD DEGs. The edge (LIMS2, ILVBL) is
potentially regulated by ETV1, ETV4, and ETV6 simultaneously, and LIMS2 was also coexpressed with ABCC5, which were both regulated by ETV4. The three target nodes were
all involved in our LUAD specific significant triangles.
I searched these three target nodes in all csGCNs. Both ILVBL and ABCC5 genes
did not form any edges in GTEx normal condition, which indicated that gaining the
(ILVBL,LIMS2), (ILVBL,LIMS2), and (LIMS2,ABCC5) edges could be related to the
formation of LUAD cancer. Both LIMS2 and ABCC5 were down-regulated in LUAD,
while ILVBL was up-regulated in LUAD. Chang et al. found that up-regulation of ETV4
resulted in the up-regulation of MSI2 in LUAD, which promotes proliferation and invasion
of LUAD[134]. Our results suggest that the up-regulation of ETV4 can both down-regulate
ABCC5 and LIMS2 and up-regulate ILVBL, which may also result in the proliferation of
LUAD. Thus, our merged csGCN-tsGRN network especially for LUAD and LUSC could
give us potential regulation information in forming different types of lung cancer.
Many studies have previously described the role four of the TFs I identified in nonsmall cell lung cancer. Zhang et al. identified ETV1 is one of the potential oncogenic TFs
that are critical to non-small cell lung cancer[135]. Wang et. al. found that overexpression
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of ETV4 upregulated PXN and MMP1 that promotes progression of non-small cell lung
cancer[136]. PXN was found in our LUSC specific GCN, and MMP1 was found in our
LUAD specific GCN. Liang et. al. studied the expression pattern of ETV6/TEL related to
non-small cell lung cancer patients on survival[137]. Kossenkov et al. found the binding
sites for ELK4 was enriched in the promoter regions of genes which are up-regulated in
tumor[138]. For the target genes, only ABCC5 was identified to have function on
gemcitabine sensitivity that related to non-small cell lung cancer[139]. Our study suggests
that the regulatory changes for ABCC5 and LIMS2 led to the correlation of these two genes
only existed in LUAD, which could be associated with LUAD cancer etiology.
The utility of biomarkers in lung cancer helps in early detection, prognosis, and
treatment guidelines, especially helpful for different subtypes of lung cancer. Our study
describes how regulatory-linked biomarker systems can be discovered in different types of
lung cancers using csGCN analysis and integration with tsGRNs. It should be noted that
our approach is generalizable and can be used to discover and interpret complex gene
expression patterns for any condition or species.
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CHAPTER FOUR
PAN CANCER NORMAL AND DEEP BRAIN GENE CO-EXPRESSION
NETWORKS
Abstract
Cancer biomarker discovery, especially in different types of cancer, is fundamental
in human health. Also, it is important to understand genetic variability and gene correlation
relationships among different regions of the human brain to better understand how different
brain regions control different functions. GCN network analysis has been proved to be a
powerful approach in identifying potential biomarker systems in a tissue-specific
condition-specific manner in previous chapters. Thus, csGCNs for all thirteen tissue of
origin unified cancer plus normal GEMs were constructed by KINC v1.0, and a deeper
normal human brain region-specific GCN was constructed using a newer version of KINC
v3.4. This chapter describes all tissue-specific csGCNs generated by KINC, which have
not been analyzed in detail yet.

Introduction
Cancer is a major issue of public health and is one of the leading causes of death
globally[102]. Every year in the US, approximately 600,000 people die from cancer. In
2020, about 10 million cases of death occurred due to different kinds of cancer
worldwide[140]. Risk factors causing cancer can be divided into intrinsic factors and
extrinsic factors. Intrinsic factors include DNA damage errors that occur randomly.
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Extrinsic factors are environmental factors, such as ultraviolet (UV) radiation, chemical
exposure, or diet[141]. Evidence shows that extrinsic factors contribute much more than
intrinsic factors in cancer development[142]. Cancer cells originate from normal cells due
to the accumulation of genomic mutations, which control cell proliferation[143]. Because
different types of cancer have different gene mutation patterns, it is important to study
cancer gene expression and regulation in a tissue-specific manner[144].
Another fundamental question I want to address is how gene co-expression differs
in each normal brain region leading to different functions. As described in Chapter 2, the
brain is probably the most complex system in the human body. Disorders or diseases related
to the human brain are among the hardest to cure. In order to recognize the differences in
disease susceptibility among different brain regions, I need to better understand the genetic
variability in regulating gene expression among different regions of this complex
organ[145]. Biomarker identification is a good way to understand a complex system,
especially for different sub-regions. One method for identifying region-specific candidate
genes by their expression patterns is gene co-expression network analysis, which groups
genes that tend to co-express and thus co-function together in similar biochemical
pathways.
With more and more public data available, data mining in biomarker discovery of
complex traits becomes feasible. The TCGA data portal and GTEx portal provide great
resources for data mining biomarker genes in tissue-specific manner. Wang et al. unified
the two datasets together by remapping reads from TCGA tumor and solid tissue normal
samples from TCGA as well as normal samples from GTEx[49]. In total, they obtained
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thirteen tissue-specific RNA-seq GEMs by combining normal samples with tumor
samples.
Gene co-expression network (GCN) analysis is a popular method to detect gene
pairwise correlations. By using samples with different conditions as input data, conditionspecific gene correlations can be found, especially by comparing normal samples with
cancer samples. Thus, this workflow can be applied to identify condition-specific gene
modules for the unified tissue-specific cancer and normal datasets. However, the threshold
using RMT was usually very high for constructing GCNs. Thus, many “real” edges and
nodes were not identified especially for region-specific edges. The concern was that too
many pairwise gene correlations were considered as noise and were removed from the
network. By using GTEx normal brain GEM as input, only six region-specific networks
can be identified. A new version of KINC v3.4 restored all edges above 0.5 and applied
several filtering steps to remove outlier clusters and biased edges. This network
construction using new KINC v3.4 generated much more potential gene correlations for
specific brain region, and thus can be used to separate normal brain regions and as a useful
resource comparing with brain related disease datasets.
In this chapter, csGCNs for the thirteen unified cancer and normal GEMs as well
as a deeper normal brain region-specific GCN were constructed by KINC. Those tissuespecific condition-specific GCNs have not been further analyzed yet.
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Material and Methods
Input GEM Matrix Pre-processing
The unified cancer and normal gene matrices were downloaded from the data
records of Wang’s research (https://doi.org/10.6084/m9.figshare.5330593)[49], which
contained GTEx normal samples, TCGA solid normal samples, and TCGA tumor samples
of each tissue type. Some tissue tumors contain more than one kind of tumor. For example,
lung cancer contains data from both LUAD and LUSC patients. All the downloaded files
were corrected for batch effects using ComBat in the R package SVAseq[50]. For each
tissue type, I merged GTEx normal, TCGA solid normal and TCGA tumor files together
into

one

GEM

using

the

merge

function

in

GEMprep

repository

(https://github.com/SystemsGenetics/GEMprep.git). There were 13 different tissue data
and thus 13 unified GEMs, one for each tissue type. The condition-specific sample
annotation matrix was collected from the original GEMs of each condition. The merged
GEM was log2 transformed, quantile normalized, and subjected to a Kolmogorov-Smirnov
test (KS Dval>0.15) using the normalization function in GEMprep repository. No outlier
sample was removed by the KS test analysis for each tissue. The whole expression matrix
for each tissue type was visualized by using t-SNE plot visualization function, also in the
GEMprep repository. In each tissue type, samples from different conditions were separated
into different clusters. All 13 GEMs were modified by removing any log2 transformed
expression values less than 0 and higher than 15 to remove bias. Each file contains the
measurements of 19,648 genes.
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The gene expression TPM profiles for normal brain sub-regions were the same as
those from Chapter two, which were downloaded from GTEx project version 7[28]. This
GEM matrix contains 1,671 samples from 13 different sub-brain regions and measurements
of expression of 56,202 genes. The pre-processing steps, including log base 2
transformation, Kolmogorov–Smirnov test (KS Dval> 0.15) to remove outlier samples,
and quantile normalization to reduce technical noise, were performed by using
preprocessCore R library[146] (https://github.com/bmbolstad/preprocessCore). No outlier
samples were removed.
Sample Clustering by t-SNE
A high-dimensional visualization method called t-SNE was performed using the
python sklearn manifold T-SNE package[147]. The input file used was the whole GTEx
brain GEM containing all 56,202 genes. The t-SNE run created a two-dimensional
initialized embedding to cluster samples into different groups. A perplexity used for each
run was 30.
Gene co-expression network construction using KINC
The

Knowledge

Independent

Network

Construction

(KINC)

software

(https://github.com/SystemsGenetics/KINC v1.0) was used to identify gene correlation
relationships for the gene expression data from the unified cancer and normal samples.
KINC was performed on nautilus PRP kubernetes portal (https://github.com/cbmckni/kinck8s-demo). KINC-nextflow was used for kubernetes (https://github.com/cbmckni/kinc-nfdemo). The algorithm underwent a cluster identification analysis by using GMMs before
calculating correlation for each gene pair. Only clusters with equal to or more than 30
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samples underwent spearman correlation. I performed GMM and correlation analysis on
each cluster. The minimum number of clusters is 1 and the maximum number of clusters
are 5 when calculating the correlation for each gene pair. RMT was utilized to determine
the significant threshold for each dataset. Condition sample annotation for each file was
used to identify condition-specific edges by using KINC.R package (https
://github.com/SystemsGenetics/KINC.R).
KINC v3.4 (https://github.com/SystemsGenetics/KINC) was used to construct
region-specific gene-co-expression networks from the pre-processed GTEx v7 normal
brain dataset. The software was written in the C++, OpenCL, CUDA and Python languages
and

used

the

Accelerated

(doi.org/10.5281/zenodo.3251112)

Computing
and

the

Engine
R

package

(ACE)
called

library
KINC.R

v3.4.2
v1.2

(https://github.com/SystemsGenetics/KINC.R). KINC v3.4 can be pulled on docker
environment on Nvidia dgx-2 node of Palmetto Cluster supercomputer. After importing
the input file, gaussian mixture models (GMMs) were applied at each pairwise gene
comparison aiming to detect any clusters based on their expression profile[118]. The
sample size equal to or more than 30 were considered as a cluster. Each pairwise
comparison could have multiple clusters and I set the maximum cluster size as 5. Then, a
pairwise expression correlation was performed for each cluster using Spearmen correlation
method. Instead of using a random matrix theory (RMT) to determine a significant
threshold for previously used KINC method, this KINC v3.4 stored all edges with gene
pair correlation higher than 0.5 and reduced the number of edges with several filtering
steps. A Pearson’s power analysis test was performed to remove clusters with low power
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using pwr_r function of R. Alpha setting limited the Type I error to the significance of
0.001, and power setting removes power at 0.8. Clusters were tested for association with
experimental conditions or any other types of annotation. Our 1,671 brain samples were
annotated with different brain sub-regions. Linear regression for quantitative conditions
and two z-tests for proportions of categorical data were performed to generate conditionspecific sub-networks. R-square values and p-values were calculated for each gene pair.
Only edges with r-square value more than 0.30 and p-value less than 0.001 were considered
as condition-specific edges. After extracted condition-specific networks, two cases of
biased condition-specific edges were removed, including lack of differential cluster
expression (DCE) and unbalanced missing data, by using KINC.R package (https
://github.com/SystemsGenetics/KINC.R). The package used a Welch’s One-way ANOVA
test to identify DCE and a Student’s t-test to compare missing data. Edges without
significant p-values for both tests (a p-value more than 0.001 for Welch’s ANOVA test and
a p-value less than 0.1 for Student’s t-test) were removed. Only edges passed all tests
became the edge in the network. Then, a valuation-based ranking method was applied to
prioritize higher ranked edges in the network based on the correlation value (similarity
score), the r-square value (for quantitative conditions) and corresponding p-value also by
using KINC.R package. The network was visualized using a python-based 3D visualization
tool. This 3D viewer helps examine pairwise gene expression scatterplots, ensure the
results as expected, and can change the parameters for filtering. This layout screen capture
was shown in Figure 4.3. The overview information of full GCN and brain region subGCNs were shown in Table 4.2.
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Results
I downloaded all 13 different tissue of origin gene expression matrices (GEMs)
containing both normal samples from GTEx and TCGA and tissue of origin cancer
samples. Even though all those gene profiles have already been re-quantified, the GEMs
still underwent preprocessing steps, including log base 2 transformation, outlier removal
by KS test, and quantile normalization. No outlier samples were identified for all thirteen
profiles. These pre-processed GEMs were used to construct condition-specific GCNs by
using KINC v1.0. The global attribute for all thirteen tissue-specific GCNs were shown in
Table 4.1. According to the t-SNE plot shown in Chapter 3 (Figure 3.1), most TCGA solid
tissue normal samples were clustered together with GTEx normal samples. For example,
in breast and liver GEM, the TCGA solid tissue normal samples shown in blue locates
together with green GTEx normal samples. While in some tissue types, TCGA solid normal
samples locate in the middle between tumor and normal samples. For example, in salivary
GEM, the TCGA solid tissue normal samples (blue) grouped as a separate cluster between
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GTEx normal samples (green) and TCGA tumor samples (orange) rather than grouped
together with GTEx normal samples. This could be due to the proximity of solid tissue
normal samples to tumor samples, which may introduce tumor environment signals in their
gene expression profile[148]. Another situation is that no clusters can be found for the
tissue samples, as shown for the cervix dataset. This is due to the lack of enough solid
tissue normal samples to form a cluster. The RMT threshold for each network were very
high, with the lowest value of 0.83. Thus, the size for condition-specific edges and genes
identified for each tissue type was relatively small.
I also downloaded and parsed the 1,671 GTEx normal brain gene expression
profiles representing 13 different sub-brain regions. This gene expression matrix contained
56,202 genes in total. The matrix underwent log base 2 transformation, outlier removal by
KS test, and quantile normalization. The density plots for the original matrix and preprocessed matrix are shown in Figure 4.1. The log base 2 transformed gene expression
values for all samples crossed from -10 to 15. The GEM reached a smaller peak around -3

Figure 4.1 Density plot for GTEx brain GEM. (A) The distribution of gene expression
values from the original log base 2 transformed GEM. (B) The distribution of gene
expression values after outlier removal and quantile normalization.
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and a higher peak around 4. Higher values mean more expression in this gene in the specific
sample. For the original GEM, the distribution for each sample was a little bit different but
they showed the same trend line. After quantile normalization, all samples were identical
in statistical properties. The quantile normalization aimed to reduce any technique noise.
Using the pre-processed GEM as input, t-SNE visualization was performed to
recognize how well those sub-regions can be separated from each other based on their gene
expression patterns. The result is shown in Figure 4.2. Sub-regions were separated into
groups even though some similar regions still group together. For example, cerebellum and
cerebellar hemisphere samples grouped together and were separated from other region
samples. Both spinal cord and substantia nigra samples were separated relatively from
other samples. All basal ganglia samples including caudate, nucleus accumbens, and
putamen samples grouped with each other as a cluster. Samples from anterior cingulate
cortex, cortex, and frontal cortex were grouped together too.

Figure 4.2 t-SNE distribution of the whole GTEx brain GEM. Each color
represents for a sub-brain region. The color labels for each sub-brain region
is shown at top left box.
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The conditional specific GCN was constructed by KINC v3.4 also using this preprocessed GEM as input. Because the pairwise correlation selected was above 0.5 instead
of the significant threshold using RMT thresholding method, many more edges were
obtained for this new version of KINC. KINC v3.4 utilized Pearson’s power analysis to
remove clusters with insufficient power, sample condition analysis by linear regression test
of quantitative conditions and two z-score tests, biased edges removal by Welch’s Oneway ANOVA test and student t-test, and a rank system to prioritize the edges by their
similarity score, r-square and p-values for quantitative conditions. A 3D network
visualization was performed (Figure 4.3). The full network contained 19,495 nodes and
2,772,557 edges in total. The network global attributes for both the full network and each
region-specific sub-network is shown in Table 4.2. The cerebellum subnetwork contains
the most condition-specific nodes and edges (15,614 nodes and 334,098 edges), while
anterior cingulate cortex BA24 subnetwork contains the least condition-specific nodes and
edges (841 nodes and 744 edges).
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Figure 4.3 Normal brain KINC 3D network visualization. Left showed the general
information of genes and nodes of this normal brain network and can be filtered by any of the
parameters. Edge scatterplot for a specific edge can be seen in the explorer. The node degree
distribution was showed. Right side is the 3D overview of the whole network. It can be
separated by different brain regions, and I can filter the similarity score to get part of the
network.
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Because this is a condition-specific network, brain region annotations were added
and region-specific sub-GCNs were generated. Table 4.3 is an example of edge identified
by KINC. The edge had a correlation of 0.95, which is very high. Two cluster indexes were
found based on the gene pairwise expression, and the cluster identified contained 379
samples and was enriched for both cortex and frontal cortex (BA9). The scatterplot of this
edge is shown in Figure 4.4. Samples showing red indicates samples grouped as a GMM
cluster. I can tell from the figure that a linear correlation for the two genes can be seen in
the red samples only. The expression pattern for the two genes did not show any correlation
for other samples.
A

B

Figure 4.4 Gene scatterplot of an example edge. (A) Variation plot for
the distribution of sample over the space of all possible gene expression
levels. (B) the actual sample distribution based on the two gene expression
profiles. Samples shown in red represents a cluster identified by GMMs
that had pairwise correlation above 0.5.
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Furthermore, gene types were counted for whole GCN nodes and nodes from all 13
region-specific sub-GCNs (Table 4.4). Of those from the whole GCN and region-specific
sub-GCNs, almost all the genes were protein-coding genes. However, there are still a lot
of non-coding genes identified in the networks. Interestingly, the gene types containing the
greatest number of nodes shown in brain GCN except for protein-coding genes were
antisense genes (1,373), lincRNAs (1,290), and pseudogenes (1074). Among all gene
types, protein-coding genes, antisense genes, lincRNAs, pseudogenes, processed
transcripts, sense intronic lncRNAs, and sense overlapping lncRNAs can be found in all
region-specific sub-GCNs.

4

85

Discussion
In this chapter, I constructed condition-specific sub-GCNs for all 13 unified tissue
profiles containing both normal samples and cancer samples. I also constructed a deeper
normal brain region-specific GCN than what was described in Chapter 2.
Condition-specific gene sets were found for each cancer type. This will be a good
resource in further investigations of cancer specific biomarker candidates. In the future,
deeper csGCNs for all thirteen tissue types need to be generated by KINC v3.4. That is
because much more condition-specific edges were observed for the GCNs generated by
KINC v3.4. As in Chapter 2, the full lung GCN network contains 58,415 edges using KINC
v 3.4, while only 9484 edges were identified with KINC v1.0. Furthermore, each tissuespecific cancer biomarker system identified by KINC needs to be validated by other
computational approaches. For example, Gene Oracle is used to identity its classification
possibility and further narrow down to fewer more significant tissue-specific conditionspecific cancer biomarkers. Another example is transcriptome state perturbation generator
(TSPG), which is used to predict the gene expression changes for our potential biomarker
systems from tumor state to healthy state for a specific patient.
For the normal brain GEM, the distribution of brain samples from different subregions were visualized by t-SNE. Samples from the same or similar regions tended to
cluster together. The region-specific GCN was constructed by using a newer version of
KINC v3.4. Instead of using higher thresholding for similarity score, I stored all gene
correlations above 0.5 and removed all biased edges. Region-specific edges were
identified. A gene type count was performed for nodes from both the whole GCN and sub-
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GCNs. Most identified genes were mRNAs, but there were still many from other gene
types. Those types of genes can reveal the regulatory mechanisms in forming different
regions of brain.
The density plot showed the distribution of gene expression values among all brain
samples. The plot indicated that very few genes were not expressed or had very high
expression values. Most genes had expression values between -3 and 4 for the log base 2
transformed GEM. According to the t-SNE visualization of the GTEx v7 brain GEM,
cerebellum and cerebellum hemispheres were clearly separated from the other sub-brain
regions. Samples from the same region tend to group together, while some brain regions
had multiple clusters. The cerebellum and cerebellum hemispheres likely grouped together
because they were collected from the same location of the brain[28]. Since the cerebellum
is at the back of the head and controls muscle movement, balance, and equilibrium[149],
the gene expression for cerebellum should be very different from other brain regions.
However, cerebral fusion occurs for diverse brain regions for different functions, and
therefore it is difficult to separate most of the sub-brain regions using their gene expression
patterns[150]. Interestingly, both cerebral cortex and cerebellum expanded greatly in their
size and the number of neurons in human evolution, but human cerebellum has expanded
even more than human cerebral cortex, suggesting the evolutionary role of cerebellum in
human behaviors and cognition[151][152].
The GCN network constructed by KINC v3.4 was much larger than the previously
constructed normal brain GCN in Chapter Two. The node degree distribution showed most
nodes had very low connectivity while very few nodes were correlated with many other
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nodes. This means this network fits the power law, as expected. All condition-specific
edges can be found for all thirteen sub-brain regions, meaning there are many gene
interactions specific for each brain region. In a previous chapter, I constructed only six subbrain region-specific GCNs from the network, with small numbers in each region-specific
network. Thus, a comparison between the two networks and the validation of relatively
low correlation edges for brain region-specificity needs to be done. With many more genes
and their correlation relationships identified in this study, this network can be a good
resource for better understanding the specificity of each brain regions and their functions
according to the molecular basis.
In conclusion, csGCNs were generated by KINC from different types of tissue
samples either for normal or cancer conditions. Those csGCNs have not been further
studied, but will be discussed and analyzed in the future for identifying biomarkers in a
tissue-specific condition-specific manner.
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CHAPTER FIVE
CONCLUSIONS AND FUTURE WORKS
In this study, I utilized condition-specific gene co-expression networks (csGCNs)
analysis as well as the integration of csGCNs with tissue-specific gene regulatory networks
(tsGRNs) for biomarker discovery. Knowledge Independent Network (KINC), a conditionspecific gene co-expression network (GCN) construction algorithm, was essential to the
work presented. By using KINC version 1.0 and KINC version 3.4, different depths of
condition-specific correlated networks were found. KINC is known for identifying
condition-specific edges by performing sample clustering before calculating correlation
similarity scores for every gene pair. This Dissertation constructed csGCNs for both normal
brain and different lung conditions by KINC, and integrated the lung csGCNs with lungspecific GRN to recognize condition-specific biomarkers.
In Chapter 2, a normal brain GCN was constructed using 1,671 GTEx v7 normal
brain datasets across 13 brain regions to identify biomarker candidates in normal brain subregions. Six brain region-specific GCNs were identified and the gene sets in these networks
were further evaluated by a deep learning-based classification method called Gene Oracle
to measure the quality of the biomarker sets. Further identification of candidate biomarkers
for those gene sets was also performed by this software. The region-specific biomarker sets
were also applied to brain tumor datasets to find their potential in separating abnormal
brain samples.
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Chapter 3 presents the GCN construction for unified lung datasets containing both
normal lung and two types of lung cancer samples using KINC v3.4. All lung conditionspecific GCNs were identified and integrated with a lung specific GRN network. Gene
Oracle was also performed for the merged gene sets in each condition to see their potential
in classification. This chapter aims to identify regulatory linked biomarker systems.
Chapter 4 describes the csGCNs constructed from all 13 different unified datasets
containing both normal samples from GTEx and TCGA solid tissue normal samples, and
cancer samples from TCGA using KINC v1.0, as well as a larger and in-depth normal
human brain region-specific GCN constructed from GTEx normal brain dataset containing
13 different brain sub-regions using KINC v3.4. All condition-specific sub-GCNs were
identified and can be used as disease specific gene sets for further classification and drug
development. The deeper normal brain region-specific GCN can be used to identify edges
that were missed by the previous GCN constructed using KINC v1.0.
In conclusion, our research applied several common systems genetics approaches,
including GCN construction, visualization, and clustering, to identify tissue-specific
condition-specific biomarker systems that have correlation or regulatory mechanisms. By
running the above algorithms and workflows, I identified biomarkers for both normal brain
and two types of lung cancers. These results demonstrate that the combination of systems
genetics approaches can be used to identify a specific set of candidate biomarkers. This
biomarker systems identification pipeline can be applied to other cancers.
It should be noted that all analyses required complex computational analysis and
Python and R coding skills. During my PhD studies, I focused on data mining on the high-
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throughput RNA sequencing datasets to identify useful biomarkers regarding to the
correlation and regulation relationships.
In the future, there are many research paths toward biomarker systems identification
and validation. The normal brain region-specific GCNs for KINC v3.4 need to be compared
with our original sub-GCNs constructed by KINC 1.0. More robust region-specific
biomarker genes can be identified for this new network, and the normal brain regionspecific biomarkers can be compared with brain tumor datasets to identify the modification
of which biomarkers especially in a specific region causes a type of brain tumor.
Furthermore, all other types of tumor specific as well as normal condition-specific GCNs
was generated. Further computational validation of those tumor candidate genes needs to
be performed, such as by Gene Oracle for classification or by transcriptome state
perturbation generator (TSPG) to predict the patient-specific gene expression changes from
tumor to healthy.
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Appendix A
Supplementary Tables

Supplemental Table A-1: GTEX-Normal Brain Gene Co-expression Network.
Supplemental Table A-2: GTEX- Normal Brain Gene Co-expression Network ModuleAttribute Enrichment.
Supplemental Table A-3: GTEX- Normal Brain Gene Co-expression Network EdgeAttribute Enrichment.
Supplemental Table A-4: Brain Tissue-Specific Gene Co-Expression Network Global
Attributes with different p-values.
Supplemental Table A-5: GTEX- Normal Brain Gene Co-expression Network Module
Functional Enrichment.
Supplemental Table A-6: Tissue-Specific Genes Functional Enrichment.
Supplemental Table A-7: Gene Type Counting.
Supplemental Table A-8: Exact Gene Type Counting for Brain GCN Genes.
Supplemental Table A-9: Unified Lung Gene Co-expression Network.
Supplemental Table A-10: GTEx Lung Gene Regulatory Network.
Supplemental Table A-11: LUAD and LUSC Specific GRN Edge Attributes.
Supplemental Table A-12: All Triangle Edges Information for LUAD and LUSC Specific
Nodes in Combined Networks.
Supplemental Table A-13: Pathway information for LUAD and LUSC specific nodes in
bipartite networks.
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The

supplemental

tables

can

be

found

at

https://drive.google.com/file/d/1H7xYdwV9Zxx0BosrVmoHH7O28pqq8eV7/view?usp=
sharing.
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Appendix B
Supplementary Figures

Supplemental Figure B-1: t-SNE visualization based on region-specific genes with
different p-values: Figure (A), (B), (C), (D) represent the genes with p-value less than 1.0e3 1.0e-5, 1.0e-15, 1.0e-20 respectively. Non-black dots represent the tissue subtypes
represented by the mini-GCN and black dots represents all other tissue types. For all basal
ganglia specific gene sets, red, orange and yellow dots represent caudate basal ganglia,
nucleus accumbent basal ganglia, and putamen basal ganglia samples respectively. The red
and orange dots from cerebellum and cerebellar hemisphere specific gene sets represent
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cerebellum and cerebellar hemisphere samples respectively. All red dots from other tissuespecific gene sets represent the particular tissue-specific samples.

Supplemental Figure B-2: Number of edges unique to 1 to 13 different brain regions for
each region.
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Supplemental Figure B-3: t-SNE based on gene expression of enriched nodes for each
region with p-value at 1.0e-10. For each t-SNE plot, the different colors represent different
regions. The first picture represents t-SNE visualization from all brain genes that collected
from brain GCN. Second picture is the t-SNE results from total number of genes that are
enriched for any of the 13 brain regions. The next 13 figures represent the gene sets for the
specific region. The blue circle represents cerebellum and cerebellar hemisphere samples,
yellow circle represents spinal cord samples, and red circle represents substantia nigra
samples.
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Supplemental Figure B-4: TCGA 4 tumor types t-SNE based on gene expression of
enriched nodes for each region. t-SNE was performed using TCGA RNAseq data from
brain region enriched genes. These genes can be enriched in more than one region. 1431
tumor samples from four tumor subtypes are shown. Tumor RNA expression profiles
sorted regions into multiple clusters. Each color represents different regions. Red
represents glioblastoma (GBM); green represents head and neck squamous cell carcinoma
(HNSC); blue represents low grade glioma (LGG); yellow represents pheochromocytoma
and paraganglioma (PCPG).
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Supplemental Figure B-5: t-SNE visualization of cortex specific genes on TCGA tumor
data for gender, race, and stage. t-SNE embedding of the 1424 tumor samples of 4 tumor
types x each corresponding region-specific gene subsets. RNA expression profiles sorted
regions into multiple clusters. Different color represents different region. (A) gender
perspective: Red represents male; blue represents female. (B) race perspective: red
represents white people; blue represents black or African American; orange represents
Asian; yellow represents American Indian or Alaska native; green represents Not reported.
(C) stage perspective: red represents stage i; blue represents stage ii; orange represents
stage iii; yellow represents stage iva; green represents stage ivb; cyan represents stage ivc;
black represents Not reported.

99

Supplemental Figure B-6: t-SNE visualization of region-specific genes for brain tumors
based on IDH mutation. The first two pictures are t-SNE plots from whole brain GCN
genes. The bottom six t-SNE plot pairs are based on brain region sub-GCN genes. For each
pair, left picture is t-SNE plots annotated by tumor type, while right panel is annotated by
the samples whether contain IDH mutation.
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Supplemental Figure B-7: Unified Lung Matrix Sample Distribution Plot. The combined
lung GEM was log base 2 transformed and quantile normalized. Different color lines
represent samples that have slightly different distribution. X-axis represents log base 2
transformed gene expression values, and y-axis represents the corresponding density.
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Supplemental Figure B-8: Lung GCN 3D Network Visualization. Red represents GTEx
normal specific edges; Blue represents TCGA normal specific edges; Green represents
TCGA LUAD specific edges; and orange represents TCGA LUSC specific edges. The grey
circle represents connectivity. Bigger the circle is, the higher connectivity the node has.
The left part is the basic information of this network, including number of total edges,
number of unique edges, number of nodes, and node degree distribution.
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